TREA

Active ingredient combinations having insecticidal and acaricidal properties

Follow

Information

  • Patent Grant
  • 9968086
  • Patent Number
    9,968,086
  • Date Filed
    Tuesday, October 20, 2015
    8 years ago
  • Date Issued
    Tuesday, May 15, 2018
    6 years ago
Information
Abstract
The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids.
Description
BACKGROUND

Field of the Invention


The present invention relates to novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) and are very suitable for control of animal pests such as insects and/or unwanted acarids.


Description of Related Art


Some of the compounds of the formula (I) are known from WO 2007/144100 and their insecticidal action has been described. The active ingredients specified in this description by their common name are known, for example, from “The Pesticide Manual” 14th ed., British Crop Protection Council 2006, and the website http://www.alanwood.net/pesticides.


However, the acaricidal and/or insecticidal efficacy and/or the activity spectrum and/or the compatibility of the known compounds with plants, especially with respect to crop plants, is not always adequate.


SUMMARY

It has now been found that active ingredient combinations comprising the compounds of the general formula (I)




embedded image



in which

  • R1 is hydrogen, amino, hydroxyl or in each case optionally C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl or C3-C6-cycloalkyl, where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, (C1-C4-alkoxy)carbonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino or (C1-C4-alkyl)C3-C6-cycloalkylamino,
  • R2 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, C1-C6-alkoxycarbonyl or C1-C6-alkylcarbonyl,
  • R3 is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C12-cycloalkyl, C3-C12-cycloalkyl-C1-C6-alkyl, where the substituents may each independently be selected from amino, C3-C6-cycloalkylamino, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C6-alkoxycarbonyl, C1-C6-alkylcarbonyl, C3-C6-trialkylsilyl or a saturated or partly saturated heterocyclic ring, an aromatic or heteroaromatic ring or a saturated, partly saturated or aromatic heterobicyclic ring, where the ring or ring system is optionally mono- or polysubstituted identically or differently by SF5, halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, aminosulphonyl, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C6-haloalkyl, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylsulphimino, C1-C4-alkylsulphimino-C1-C4-alkyl, C1-C4-alkylsulphimino-C2-C5-alkylcarbonyl, C1-C4-alkylsulphoximino, C1-C4-alkylsulphoximino-C1-C4-alkyl, C1-C4-alkylsulphoximino-C2-C5-alkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-alkylcarbonyl, C3-C6-trialkylsilyl, benzyl C2-C6-alkenyl, C2-C6-alkynyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, or a 3- to 6-membered ring, where the ring may optionally be substituted by C1-C6-alkyl, halogen, cyano, nitro, halo(C1-C6)-alkyl, C1-C6-alkoxy or halo(C1-C6)-alkoxy, or
  • R3 is C1-C6-alkoxycarbonyl, C1-C6-alkylcarbonyl, C1-C6-alkylaminocarbonyl or di(C1-C6)alkylaminocarbonyl, or
  • R3 is additionally a mono- or polysubstituted identically or differently, 5- or 6-membered aromatic or heteroaromatic ring, a 4, 5- or 6-membered partly saturated ring or saturated heterocyclic ring, or a saturated, partly saturated or aromatic heterobicyclic ring which may optionally contain one to three heteroatoms from the group of O, S and N, where the substituents are each independently selected from SF5, halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C6-haloalkyl, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkylsulphimino, C1-C4-alkylsulphimino-C1-C4-alkyl, C1-C4-alkylsulphimino-C1-C5-alkylcarbonyl, C1-C4-alkylsulphoximino, C1-C4-alkylsulphoximino-C1-C4-alkyl, C1-C4-alkylsulphoximino-C2-C5-alkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-alkylcarbonyl, C3-C6-trialkylsilyl, C2-C6-alkenyl, C2-C6-alkynyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, or a 3- to 6-membered ring, where the ring may optionally be substituted by C1-C6-alkyl, halogen, cyano, nitro, halo(C1-C6)-alkyl, C1-C6-alkoxy or halo(C1-C6)-alkoxy,
  • R2 and R3 may be joined to one another via two to six carbon atoms and form a ring which optionally additionally contains a further nitrogen, sulphur or oxygen atom and may optionally be mono- to tetrasubstituted by C1-C2-alkyl, C1-C2-haloalkyl, halogen, cyano, amino C1-C2-alkoxy or C1-C2-haloalkoxy,
  • R2, R3 together are additionally ═S(C1-C4-alkyl)2, ═S(O)(C1-C4-alkyl)2,
  • R4 is hydrogen, halogen, cyano, nitro C1-C4-alkyl, C1-C4-haloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C1-C4-alkoxy, C1-C4-haloalkoxy, SF5, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C4-alkoxy)imino, (C1-C4-alkyl)(C1-C4-alkoxy)imino, (C1-C4-haloalkyl)(C1-C4-alkoxy)imino or C3-C6-trialkylsilyl, or


two R4 via adjacent carbon atoms form a ring which is —(CH2)3—, —(CH2)4—, —(CH2)5—, —(CH═CH—)2—, —OCH2O—, —O(CH2)2O—, —OCF2O—, —(CF2)2O—, —O(CF2)2O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,


two R4 via adjacent carbon atoms additionally form the following fused rings which are optionally mono- or polysubstituted identically or differently, where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C3-C6-halocycloalkyl, halogen, C1-C6-alkoxy, C1-C4-alkylthio(C1-C6-alkyl), C1-C4-alkylsulphinyl(C1-C6-alkyl), C1-C4-alkylsulphonyl(C1-C6-alkyl), C1-C4-alkylamino, di-(C1-C4-alkyl)amino or C3-C6-cycloalkylamino,




embedded image


  • n is 0 to 3,

  • R5 is C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C1-C6-halocycloalkyl, C2-C6-alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, halogen, cyano, nitro or C3-C6-trialkylsilyl,

  • QX is an optionally singly or multiply, identically or differently R7-substituted, aromatic or heteroaromatic 5- to 6-membered ring which may contain 1-3 heteroatoms from the group of N, S, O,

  • A is optionally mono- or polysubstituted —(C1-C6-alkylene)-, —(C2-C6-alkenylene)-, —(C2-C6-alkynylene)-, —R8—(C3-C6-cycloalkyl)-R8—, —R8—O—R8—, —R8—S—R8—, —R8—S(═O)—R8—, —R8—S(═O)2—R8—, —R8—N(C1-C6-alkyl)-R8—, —R8—C═NO(C1-C6-alkyl)-R8, —CH[CO2(C1-C6-alkyl)-, —R8—C(═O)—R8, —R8—C(═O)NH—R8, R8—C(═O)N(C1-C6-alkyl)-R8, —R8—C(═O)NHNH—R8—, —R8—C(═O)N(C1-C6-alkyl)-NH—R8—, —R8—C(═O)NHN(C1-C6-alkyl)-R8, —R8—O(C═O)—R8, —R8—O(C═O)NH—R8, —R8—O(C═O)N(C1-C6-alkyl)-R8, —R8—S(═O)2NH—R8, —R8—S(═O)2N(C1-C6-alkyl)-R8, —R8—S(C═O)—R8, —R8—S(C═O)NH—R8, —R8—S(C═O)N(C1-C6-alkyl)-R8, —R8—NHNH—R8, —R8—NHN(C1-C6-alkyl)-R8, —R8—N(C1-C6-alkyl)-NH—R8, —R8—N(C1-C6-alkyl)-N(C1-C6-alkyl)-R8, —R8—N═CH—O—R8, —R8—NH(C═O)O—R8, —R8—N(C1-C6-alkyl)-(C═O)O—R8, —R8—NH(C═O)NH—R8, —R8—NH(C═S)NH—R8, —R8—NHS(═O)2—R8, R8—NH—R8, R8—C(═O)—C(═O)—R8, R8—C(OH)—R8, R8—NH(C═O)—R8, R8-Qz-R8, R8—C(═N—NR′2)—R8, R8—C(═C—R′2)—R8 or —R8—N(C1-C6-alkyl)S(═O)2—R8,



where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkyl, amino, (C1-C6-alkyl)amino, di(C1-C6-alkyl)amino, C3-C6-cycloalkyl


where —(C3-C6-cycloalkyl)- in the ring may optionally contain 1 to 2 heteroatoms selected from the group of N, S, O,

  • R8 is linear or branched —(C1-C6-alkylene)- or a direct bond,


where two or more R8 are independently linear or branched-(C1-C6-alkylene)- or a direct bond,


for example R8—O—R8— is —(C1-C6-alkylene)-O—(C1-C6-alkylene)-, —(C1-C6-alkylene)-O—, —O—(C1-C6-alkylene)-, or —O—,


where R′ is alkyl, alkylcarbonyl, alkenyl, alkynyl, which may optionally be mono- or poly-halogen-substituted,

  • Qz is a 3- to 4-membered, partly saturated or saturated, or a 5- to 6-membered, partly saturated, saturated or aromatic ring or a 6- to 10-membered bicyclic ring system,


where the ring or bicyclic ring system may optionally contain 1-3 heteroatoms from the group of N, S, O,


where the ring or bicyclic ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carbamoyl, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C6-alkyl)carbonyl, (C1-C6-alkoxy)carbonyl, (C1-C6-alkyl)aminocarbonyl, di-(C1-C4-alkyl)aminocarbonyl,

  • QY is a 5- or 6-membered, partly saturated or saturated heterocyclic or heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system, where the ring or ring system is optionally mono- or polysubstituted, identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C6-alkyl)carbonyl, (C1-C6-alkoxy)carbonyl, (C1-C6-alkyl)aminocarbonyl, di-(C1-C4-alkyl)aminocarbonyl, tri-(C1-C2)alkylsilyl, (C1-C4-alkyl)(C1-C4-alkoxy)imino,


or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy,

  • R7 is hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkoxy or




embedded image


  • R9 is independently hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, halogen, cyano, nitro, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio or C1-C4-haloalkylthio,

  • p is 0 to 4,

  • Z is N, CH, CF, CCl, CBr or Cl,



the compounds of the general formula (I) also including N-oxides and salts (I),


and one or more further insecticides and/or acaricides from the group (II):


(1) Acetylcholinesterase (AChE) inhibitors, for example


carbamates, for example alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or


organophosphates, for example acephate, azamethiphos, azinphos (-methyl, -ethyl), cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos (-methyl), coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl)salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion (-methyl), phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos (-methyl), profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion.


(2) GABA-gated chloride channel antagonists, for example


organochlorines, for example chlordane and endosulfan (alpha-); or


fiproles (phenylpyrazoles), for example ethiprole, fipronil, pyrafluprole and pyriprole.


(3) Sodium channel modulators/voltage-dependent sodium channel blockers, for example


pyrethroids, for example acrinathrin, allethrin (d-cis-trans, d-trans), bifenthrin, bioallethrin, bioallethrin-S-cyclopentenyl, bioresmethrin, cycloprothrin, cyfluthrin (beta-), cyhalothrin (gamma-, lambda-), cypermethrin (alpha-, beta-, theta-, zeta-), cyphenothrin [(1R)-trans-isomers], deltamethrin, dimefluthrin, empenthrin [(EZ)-(1R)-isomers], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (tau-), halfenprox, imiprothrin, metofluthrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, profluthrin, pyrethrins (pyrethrum), resmethrin, RU 15525, silafluofen, tefluthrin, tetramethrin [(1R)-isomers], tralomethrin, transfluthrin and ZXI 8901; or DDT; or methoxychlor.


(4) Nicotinergic acetylcholine receptor agonists, for example


neonicotinoids, for example acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam; or


nicotine.


(5) Allosteric acetylcholine receptor modulators (agonists), for example


spinosyns, for example spinetoram and spinosad.


(6) chloride channel activators, for example


avermectins/milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin.


(7) Juvenile hormone analogues, for example hydroprene, kinoprene, methoprene; or fenoxycarb; pyriproxyfen.


(8) Active ingredients with unknown or nonspecific mechanisms of action, for example


fumigants, for example methyl bromide and other alkyl halides; or


chloropicrin; sulphuryl fluoride; borax; tartar emetic.


(9) Selective antifeedants, for example pymetrozine; or flonicamid.


(10) mite growth inhibitors, for example clofentezine, diflovidazin, hexythiazox, etoxazole.


(11) microbial disruptors of the insect gut membrane, for example Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and BT plant proteins, for example Cry1Ab, Cry1Ac, Cry1Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34/35Ab1.


(12) Oxidative phosphorylation inhibitors, ATP disruptors, for example diafenthiuron; or


organotin compounds, for example azocyclotin, cyhexatin, fenbutatin oxide; or


propargite; tetradifon.


(13) Oxidative phosphorylation decouplers acting by interrupting the H proton gradient, for example chlorfenapyr and DNOC.


(14) Nicotinergic acetylcholine receptor antagonists, for example bensultap, cartap (hydrochloride), thiocylam, and thiosultap (sodium).


(15) Chitin biosynthesis inhibitors, type 0, for example benzoylureas, for example bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron.


(16) Chitin biosynthesis inhibitors, type 1, for example buprofezin.


(17) Moulting disruptors, for example cyromazine.


(18) Ecdysone agonists/disruptors, for example diacylhydrazines, for example chromafenozide, halofenozide, methoxyfenozide and tebufenozide.


(19) Octopaminergic agonists, for example amitraz.


(20) Complex-III electron transport inhibitors, for example hydramethylnone; acequinocyl; fluacrypyrim.


(21) Complex-I electron transport inhibitors, for example from the group of the METI acaricides, for example fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad, tolfenpyrad; or rotenone (Derris).


(22) Voltage-dependent sodium channel blockers, for example indoxacarb; metaflumizone.


(23) Inhibitors of acetyl-CoA carboxylase, for example tetronic acid derivatives, for example spirodiclofen and spiromesifen; or tetramic acid derivatives, for example spirotetramat.


(24) Complex-IV electron transport inhibitors, for example phosphines, for example aluminium phosphide, calcium phosphide, phosphine, zinc phosphide; or cyanide.


(25) Complex-II electron transport inhibitors, for example cyenopyrafen.


(28) Ryanodine receptor effectors, for example


diamides, for example chlorantraniliprole and flubendiamide.


Further active ingredients with unknown mechanism of action, for example amidoflumet, azadirachtin, benclothiaz, benzoximate, bifenazate, bromopropylate, chinomethionat, cryolite, cyantraniliprole (Cyazypyr), cyflumetofen, dicofol, diflovidazin, fluensulfone, flufenerim, flufiprole, fluopyram, fufenozide, imidaclothiz, imicyafos, iprodione, pyridalyl, pyrifluquinazon and iodomethane; and also preparations based on Bacillus firmus (I-1582, BioNeem, Votivo), further compounds such as dichloropropene, oil (for example petroleum), metaldehyde, metam-sodium, and the following known active compounds:


3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide (known from WO2005/077934), 4-{[(6-bromopyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-fluoropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(2-chloro-1,3-thiazol-5-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(5,6-dichloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115646), 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(6-chloropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), 4-{[(6-chloropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), {[1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ4-sulphanylidene}) cyanamide (known from WO2007/149134) and its diastereomers {[(1R)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ4-sulphanylidene}cyanamide (A) and {[(1S)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ4-sulphanylidene}cyanamide (B) (likewise known from WO2007/149134) and sulfoxaflor (likewise known from WO2007/149134) and its diastereomers [(R)-methyl(oxido) {(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ4-sulphanylidene]cyanamide (A1) and [(S)-methyl(oxido) {(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ4-sulphanylidene]cyanamide (A2), designated as diastereomer group A (known from WO 2010/074747, WO 2010/074751), [(R)-methyl(oxido){(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ4-sulphanylidene]cyanamide (B1) and [(S)-methyl(oxido) ({(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ4-sulphanylidene]cyanamide (B2), designated as diastereomer group B (likewise known from WO 2010/074747, WO 2010/074751), and 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one (known from WO2006/089633), 3-(4′-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2-one (known from WO2008/067911), 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulphinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (known from WO2006/043635), [(3 S,4aR,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-6,12-dihydroxy-4,12b-dimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-4-yl]methyl cyclopropanecarboxylate (known from WO2008/066153), 2-cyano-3-(difluoromethoxy)-N,N-dimethylbenzenesulphonamide (known from WO2006/056433), 2-cyano-3-(difluoromethoxy)-N-methylbenzenesulphonamide (known from WO2006/100288), 2-cyano-3-(difluoromethoxy)-N-ethylbenzenesulphonamide (known from WO2005/035486), 4-(difluoromethoxy)-N-ethyl-N-methyl-1,2-benzothiazol-3-amine 1,1-dioxide (known from WO2007/057407), N-[1-(2,3-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine (known from WO2008/104503), {1′-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole-3,4′-piperidin]-1 (2H)-yl}(2-chloropyridin-4-yl)methanone (known from WO2003/106457), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO2009/049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from WO2009/049851), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004/099160), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,3-trifluoropropyl)malononitrile (known from WO2005/063094), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,4,4,4-pentafluorobutyl)malononitrile (known from WO2005/063094), 8-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenoxy]-3-[6-(trifluoromethyl)pyridazin-3-yl]-3-azabicyclo[3.2.1]octane (known from WO2007/040280), 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl methyl carbonate (known from JP2008/110953), 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl acetate (known from JP2008/110953), PF1364 (CAS Reg. No. 1204776-60-2) (known from JP2010/018586), 5-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 5-[5-(2-chloropyridin-4-yl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide (known from WO2005/085216), 4-{[(6-chloropyridin-3-yl)methyl](cyclopropyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](ethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](methyl)amino}-1,3-oxazol-2(5H)-one (all known from WO2010/005692), NNI-0711 (known from WO2002096882), 1-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-3-isobutylphenyl]-N-isobutyryl-3,5-dimethyl-1H-pyrazole-4-carboxamide (known from WO2002096882), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-1,2-diethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), (5RS,7RS;5RS,7SR)-1-(6-chloro-3-pyridylmethyl)-1,2,3,5,6,7-hexahydro-7-methyl-8-nitro-5-propoxyimidazo[1,2-a]pyridine (known from WO2007/101369), 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713), 2-{6-[2-(pyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713)


are very suitable for control of animal pests such as insects and/or acaricides. The active ingredients of group (II) are, in accordance with the IRAC classification, assigned to different classes and groups according to their mechanism of action.







DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

If, within this description, the short form of the common name of an active ingredient is used, this in each case encompasses all common derivatives, such as the esters and salts, and isomers, especially optical isomers, especially the commercial form or forms. If an ester or salt is referred to by the common name, this also refers in each case to all other common derivatives, such as other esters and salts, the free acids and neutral compounds, and isomers, especially optical isomers, especially the commercial form or forms. The chemical compound names mentioned refer to at least one of the compounds encompassed by the common name, frequently a preferred compound.


Surprisingly, the insecticidal and/or acaricidal action of the inventive active ingredient combinations is much higher than the total of the actions of the individual active ingredients. There is an unforeseeable true synergistic effect and not just complementary action.


Preferred combinations comprise at least one of the active ingredients of the formula (I) specified as preferred, more preferred, even more preferred or especially preferred and one or more active ingredients selected from the group (II).


Preferred, more preferred, even more preferred or especially preferred are active ingredients of the formula (I) where




  • R1 is preferably hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, cyano(C1-C6-alkyl), C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkylthio-C1-C4-alkyl, C1-C4-alkylsulphinyl-C1-C4-alkyl or C1-C4-alkylsulphonyl-C1-C4-alkyl,

  • R1 is more preferably hydrogen, methyl, ethyl, cyclopropyl, cyanomethyl, methoxymethyl, methylthiomethyl, methylsulphinylmethyl or methylsulphonylmethyl,

  • R1 is even more preferably hydrogen,

  • R2 is preferably hydrogen or C1-C6-alkyl.

  • R2 is more preferably hydrogen or methyl.

  • R2 is even more preferably hydrogen.

  • R3 is preferably hydrogen or in each case optionally mono- or polysubstituted identically or differently, C1-C4-alkyl, C1-C4-alkoxy, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, where the substituents may each independently be selected from halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-alkoxycarbonyl, C1-C4-alkylcarbonyl or a phenyl ring or a 4, 5- or 6-membered, aromatic partly saturated or saturated heterocyclic ring, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, NO2, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C6-alkyl)carbonyl, (C1-C6-alkoxy)carbonyl or

  • R3 is preferably C2-C4-alkoxycarbonyl, C2-C4-alkylcarbonyl, C2-C4-alkylaminocarbonyl or C2-C4-dialkylaminocarbonyl, or

  • R3 is preferably a phenyl ring, a 5- or 6-membered aromatic heterocyclic ring or a 4-, 5- or 6-membered partly saturated or saturated heterocyclic ring which may contain 1-3 heteroatoms from the group of N, S, O, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, NO2, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, C1-C4-alkylamino, di-(C1-C4-alkyl)amino, C3-C6-cycloalkylamino, (C1-C4-alkyl)carbonyl, (C1-C4-alkoxy)carbonyl,

  • R3 is more preferably hydrogen or in each case optionally mono- or polysubstituted identically or differently, C1-C4-alkyl, or C3-C6-cycloalkyl, where the substituents may each independently be selected from halogen, cyano, carboxyl, hydroxyl, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C2-C4-alkoxycarbonyl, C2-C6-alkylcarbonyl or a phenyl ring or a 4-, 5- or 6-membered aromatic, partly saturated or saturated heterocyclic ring, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, or

  • R3 is more preferably C2-C4-alkoxycarbonyl, C2-C4-alkylcarbonyl, C2-C4-alkylaminocarbonyl, or

  • R3 is more preferably a phenyl ring, a 5- or 6-membered aromatic heterocyclic ring or a 4-, 5- or 6-membered partly saturated or saturated heterocyclic ring which may contain 1-3 heteroatoms from the group of N, S, O, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C2-C4-haloalkenyl, C2-C4-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carbamoyl, NO2, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, or

  • R3 is even more preferably hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclobutyl, azetidine, oxetane, thietane, pyrrolidine, pyrazolidine, imidazolidine, imidazolidinone, tetrahydrofuran, tetrahydrothiophene, tetrahydrothiophene dioxide, thiazoline, thiazolidine, piperidine, piperazine, tetrahydropyran, dihydrofuranone, dioxane, morpholine, thiomorpholine, thiomorpholine dioxide, phenyl, pyridyl, or

  • R3 is especially preferably hydrogen, methyl, isopropyl, cyclopropyl or tert-butyl.

  • R4 is preferably hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, halogen, cyano, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio or C1-C4-haloalkylthio,



two adjacent R4 radicals are likewise preferably —(CH2)3—, —(CH2)4—, —(CH2)5—, —(CH═CH—)2—, —OCH2O—, —O(CH2)2O—, —OCF2O—, —(CF2)2O—, —O(CF2)2O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,

  • R4 is more preferably hydrogen, C1-C4-alkyl, C1-C2-haloalkyl, halogen, cyano or C1-C2-haloalkoxy,


two adjacent R4 radicals are more preferably —(CH2)4—, —(CH═CH—)2—, —O(CH2)2O—, —O(CF2)2O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,

  • R4 is even more preferably hydrogen, methyl, trifluoromethyl, cyano, fluorine, chlorine, bromine, iodine or trifluoromethoxy. Even more preferably, two adjacent R4 radicals are also —(CH2)4—, or —(CH═CH—)2—.
  • R4 is especially preferably chlorine, fluorine or bromine,
  • R4 is also especially preferably iodine or cyano,


two adjacent R4 radicals are especially preferably —(CH═CH—)2

  • n is preferably 0, 1, 2,
  • n is more preferably 1 or 2,
  • n is even more preferably 1,
  • R5 is preferably C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C6-halocycloalkyl, C2-C6-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, C2-C4-haloalkynyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl, halogen, cyano, nitro or C3-C6-trialkylsilyl,
  • R5 is more preferably C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl, C1-C6-halocycloalkyl, C2-C6-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, C2-C4-haloalkynyl, C1-C4-alkoxy, C1-C4-haloalkoxy, fluorine, chlorine, bromine, iodine, cyano, nitro or C3-C6-trialkylsilyl,
  • R5 is even more preferably methyl, fluorine, chlorine, bromine or iodine,
  • R5 is especially preferably methyl or chlorine,
  • QX is preferably an optionally singly or multiply, identically or differently R7-substituted 5-6 membered heteroaromatic ring which may contain 1-3 heteroatoms from the group of N, O, S, or is phenyl,
  • QX is more preferably an optionally singly or multiply, identically or differently R7-substituted, 5- or 6-membered ring selected from the group consisting of furan, thiophene, triazole, imidazole, thiazole, oxazole, isoxazole, isothiazole, thiadiazole, oxadiazole, pyrrole, pyridine, pyrimidine, pyridazine, pyrazine, phenyl or pyrazole,
  • QX is even more preferably thiazole, oxazole, pyrrole, imidazole, triazole, pyrimidine, phenyl or pyrazole monosubstituted by the R7 group




embedded image


where Z, R and p may have the general definitions specified above or the preferred or more preferred definitions specified below,

  • A is preferably optionally mono- or polysubstituted —(C1-C4-alkylene)-, —(C2-C4-alkenylene)-, —(C2-C4-alkynylene)-, —R8—(C3-C6-cycloalkyl)-R8—, —R8—O—R8—, —R8—S—R8—, —R8—S(═O)—R8—, —R8—S(═O)2—R8—, —R8—NH—(C1-C4-alkyl)-, —R8—N(C1-C4-alkyl)-R8, —R8—C═NO(C1-C4-alkyl), —R8—C(═O)—R8, —R8—C(═S)—R8, —R8—C(═O)NH—R8, R8—C(═O)N(C1-C4-alkyl)-R8, —R8—S(═O)2NH—R8, —R8—S(═O)2N(C1-C4-alkyl)- R8, —R8—NH(C═O)O—R8, —R8—N(C1-C4-alkyl)-(C═O)O—R8, —R8—NH(C═O)NH—R8, —R8—NHS(═O)2—R8, —R8—N(C1-C4-alkyl)S(═O)2—R8, R8—NH—R8, R8—C(═O)—C(═O)—R8, R8—C(OH)—R8, R8-Qz-R8,


where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C1-C6-alkyl, C1-C6-alkoxy or halogen-C1-C6-alkyl,


where Qz may have the general definitions specified above or the preferred or more preferred definitions specified below,

  • A is more preferably —CH2—, —CH2O—, —CH2OCH2—, —CH2S—, —CH2SCH2—, —CH2N(C1-C4-alkyl)-, —CH2N(C1-C4-alkyl)CH2—, —CH(Hal)-, —C(Hal)2-, —CH(CN)—, CH2(CO)—, CH2(CS)—, CH2CH(OH)—, -cyclopropyl-, CH2(CO)CH2—, —CH(C1-C4-alkyl)-, —C(di-C1-C6-alkyl)-, —CH2CH2—, —CH═CH—, —C≡C—, —C═NO(C1-C6-alkyl), —C(═O)(C1-C4-alkyl)-,
  • A is even more preferably —CH2—, —CH(CH3), C(CH3)2, —CH2CH2—, —CH(CN)—, —CH2O— or —C(═O)—CH2—,
  • A is especially preferably CH2, CH(CH3), —CH2O— or —C(═O)—CH2—,
  • Qz is preferably a 3- to 4-membered, partly saturated or saturated, or a 5 to 6-membered, partly saturated, saturated or aromatic ring, where the ring may optionally contain 1-3 heteroatoms from the group of N, S, O,


where the ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl,

  • Qz is more preferably a 3- to 4-membered, partly saturated or saturated, or a 5-membered, partly saturated, saturated or aromatic ring, where the ring may optionally contain 1-2 heteroatoms from the group of N, S, O,


where the ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl,

  • Qz is even more preferably azetidine, oxetane or thietane, pyrrolidine, pyrroline, pyrazolidine, pyrazoline, imidazolidine, imidazolidone, imidazoline, tetrahydrofuran, tetrahydrothiophene, thiazolidine, isothiazolidine, isoxazoline,


which is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, methyl, ethyl, isopropyl, hydroxyl, methoxy, trifluoromethoxy, fluorine, chlorine, bromine, cyano, difluoromethyl, trifluoromethyl,

  • R7 is preferably C1-C6-alkyl or the radical




embedded image


  • R7 is additionally preferably C3-C6-cycloalkoxy,

  • R7 is more preferably methyl or the radical





embedded image


  • R9 is independently preferably hydrogen, halogen, cyano, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl, C1-C4-haloalkoxy, C1-C4-haloalkylsulphonyl or (C1-C4-alkyl)C1-C4-alkoxyimino,

  • R9 is independently more preferably hydrogen, halogen, cyano or C1-C4-haloalkyl,

  • R9 is independently even more preferably fluorine, chlorine or bromine,

  • R9 is especially preferably chlorine,

  • p is preferably 1, 2 or 3,

  • p is more preferably 1 or 2,

  • p is even more preferably 1,

  • Z is preferably N, CH, CF, CCl, CBr or Cl,

  • Z is more preferably N, CH, CF, CCl or CBr,

  • Z is even more preferably N, CCl or CH,

  • R8 is preferably linear or branched —(C1-C4-alkylene)- or a direct bond

  • R8 is more preferably methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl or isobutyl or a direct bond

  • R8 is even more preferably methyl or ethyl or a direct bond

  • QY is preferably a 5- or 6-membered, partly saturated or saturated heterocyclic or heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system, where the heteroatoms may be selected from the group of N, S, O, where the ring or ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C1-C4-alkylsulphinyl, C1-C4-alkylsulphonyl, C1-C4-haloalkylthio, C1-C4-haloalkylsulphinyl, C1-C4-haloalkylsulphonyl,



or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy,

  • QY is more preferably is an optionally mono- or polysubstituted 5- or 6-membered heteroaromatic ring from the group of Q-1 to Q-53 and Q-58 to Q-59, Q62 to Q63, an aromatic 9-membered fused heterobicyclic ring system Q-54 to Q-56 and a 5-membered heterocyclic ring Q-60 to Q-61, where the substituents may each independently be selected from C1-C3-alkyl, C1-C3-haloalkyl, C1-C2-alkoxy, halogen, cyano, hydroxyl, nitro or C1-C2-haloalkoxy,


or where the substituents may each independently be selected from phenyl or einem 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, NO2, hydroxyl, C1-C4-alkoxy, C1-C4-haloalkoxy,

  • QY is even more preferably an optionally mono- or polysubstituted 5- or 6-membered heteroaromatic ring from the group of Q-36 to Q-40, Q43, Q-58 to Q-59, Q62, Q63, an aromatic 9-membered fused heterobicyclic ring system Q-54 to Q-56 and a 5-membered heterocyclic ring Q-60 to Q-61, where the substituents may each independently be selected from C1-C3-alkyl, C1-C3-haloalkyl, C1-C2-alkoxy, halogen, cyano, hydroxyl, nitro or C1-C2-haloalkoxy,


or where the substituents may each independently be selected from phenyl or einem 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C6-halocycloalkyl, halogen, cyano, nitro, C1-C4-alkoxy, C1-C4-haloalkoxy,

  • QY is especially preferably an optionally mono- or polysubstituted identically or differently, heteroaromatic ring from the group of Q-37, Q-38, Q-39, Q-40, Q43, Q-58, Q-59, Q62 and Q63, and a 5-membered heterocyclic ring Q-60, where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl and heptafluoroisopropyl


or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl and heptafluoroisopropyl,




embedded image


embedded image


embedded image


embedded image


embedded image


The rings or ring systems shown above may optionally each independently be additionally substituted by oxo, thio, (═O)═NH, (═O)═N—CN, (═O)2. Examples include tetrahydrothiophene dioxide, imidazolidone.


The oxo group as a substituent on a ring carbon atom is then, for example, a carbonyl group in the heterocyclic ring. As a result, lactones and lactams are preferably also included. The oxo group can also occur on the ring heteroatoms which can occur in different oxidation states, for example in the case of N and S, and then form, for example, the divalent groups —N(O)—, —S(O)— (or SO for short) and —S(O)2— (or SO2 for short) in the heterocyclic ring. In the case of —N(O)— and —S(O)— groups, both enantiomers are included in each case.


Substituents other than the oxo group may also be bonded to a heteroatom on a heterocyclic ring, for example to a nitrogen atom when a hydrogen atom on the nitrogen atom of the base skeleton is replaced. In the case of the nitrogen atom and also of other heteroatoms, for example of the sulphur atom, further substitution to form quarternary ammonium compounds or sulphonium compounds is also a possibility.


More particularly, the compounds of the formula (I) may be present in the form of different regioisomers: for example in the form of mixture of compounds with the definition of Q62 and Q63 or in the form of mixtures of Q58 and Q59. The invention therefore also encompasses active ingredient combinations comprising mixtures of compounds of the formula (I) where QY is defined as Q62 and Q63, and Q58 and Q59, and the compounds may be present in different mixing ratios, and one or more active ingredients from group (II). Preference is given to mixing ratios of compounds of the formula (I) in which the QY radical is Q62 or Q58 to compounds of the formula (I) in which the Qy radical is Q63 or Q59 of 60:40 to 99:1, more preferably of 70:30 to 97:3, even more preferably of 80:20 to 95:5. Especially preferred are the following mixing ratios of a compound of the formula (I) where QY is defined as Q62 or Q58 to the compound of the formula (I) where QY is defined as Q63 or Q59: 80:20; 81:19; 82:18; 83:17; 84:16; 85:15, 86:14; 87:13; 88:12; 89:11; 90:10, 91:9; 92:8; 93:7; 96:6; 95:5.


Additionally preferred are active ingredient combinations comprising at least one active ingredient of the formula (I-1)




embedded image



in which

  • R3 is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C12-cycloalkyl, C3-C12-cycloalkyl-C1-C6-alkyl, where the substituents may each independently be selected from halogen, amino, cyano, nitro, hydroxyl, C1-C6-alkyl, C3-C6-cycloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C2-C6-alkoxycarbonyl, C1-C6-alkylcarbonyl C3-C6-cycloalkylamino or a 5- or 6-membered heteroaromatic ring,
  • R4 is halogen, cyano or methyl,
  • R5 is methyl or chlorine,
  • Z is N, CCl or CH,
  • Qy an optionally mono- or polysubstituted 5- or 6-membered heteroaromatic ring from the group of Q-36 to Q-40, Q43, Q-58 to Q-59, Q62, Q63, an aromatic 9-membered fused heterobicyclic ring system Q-54 to Q-56 and a 5-membered heterocyclic ring Q-60 to Q-61, where the substituents may each independently be selected from C1-C3-alkyl, C1-C3-haloalkyl, C1-C2-alkoxy, halogen, cyano, hydroxyl, nitro or C1-C2-haloalkoxy,


where the compounds of the formula (I-1) may be present in the form of salts, and one or more active ingredients selected from group (II).


More preferred combinations are those comprising at least one of the active ingredients of the formula (I-1) specified as preferred, more preferred, even more preferred or especially preferred, and one or more active ingredients selected from group (II).


Preferred, more preferred, even more preferred or especially preferred active ingredients are those of the formula (I-1) where

  • R3 is preferably hydrogen or in each case optionally mono- or polysubstituted identically or differently, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, where the substituents may each independently be selected from halogen, cyano, amino, hydroxyl, C1-C6-alkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, C1-C4-alkylthio, C3-C6-cycloalkyl, a 5- or 6-membered heteroaromatic ring containing 1-2 heteroatoms from the group of N, O, S, where no two oxygen atoms in the ring are adjacent,
  • R3 is more preferably one of the following radicals:




embedded image


  • R4 is preferably halogen, cyano or methyl,

  • R4 is more preferably chlorine and cyano,

  • R4 is likewise more preferably bromine, fluorine, iodine or methyl,

  • R5 is preferably and more preferably methyl,

  • Z is preferably N or CH, QY is preferably an optionally mono- or polysubstituted identically or differently, heteroaromatic ring from the group of Q-37, Q-38, Q-39, Q-40, Q43, Q-58, Q-59, Q62 and Q63, and a 5-membered heterocyclic ring Q-60, where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl and heptafluoroisopropyl.

  • QY is more preferably an optionally mono- or polysubstituted identically or differently, heteroaromatic ring from the group of Q-58 and Q-59, where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, n-heptafluoropropyl and isoheptafluoropropyl.



More particularly, the compounds of the formula (I-1) may be present in the form of different regioisomers, for example in the form of mixtures of compounds with the definition of Q62 and Q63 or in the form of mixtures of Q58 and Q59. The invention therefore also includes active ingredient combinations comprising mixtures of compounds of the formula (I-1) where QY is defined as Q62 and Q63, and Q58 and Q59, and the compounds may be present in different mixing ratios, and one or more active ingredients from the group (II). Preference is given to mixing ratios of compounds of the formula (I) in which the QY radical is Q62 or Q58 to compounds of the formula (I) in which the Qy radical is Q63 or Q59 of 60:40 to 99:1, more preferably of 70:30 to 97:3, even more preferably of 80:20 to 95:5. Especially preferred are the following mixing ratios of a compound of the formula (I) where QY is defined as Q62 or Q58 to the compound of the formula (I) where QY is defined as Q63 or Q59: 80:20; 81:19; 82:18; 83:17; 84:16; 85:15, 86:14; 87:13; 88:12; 89:11; 90:10, 91:9; 92:8; 93:7; 96:6; 95:5.


Additionally preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

  • acrinathrin
  • alpha-cypermethrin
  • betacyfluthrin
  • cyhalothrin
  • cypermethrin
  • deltamethrin
  • esfenvalerate
  • etofenprox
  • fenpropathrin
  • fenvalerate
  • flucythrinate
  • lambda-cyhalothrin
  • gamma-cyhalothrin
  • permethrin
  • tau-fluvalinate
  • transfluthrin
  • zeta-cypermethrin
  • cyfluthrin
  • bifenthrin
  • tefluthrin
  • eflusilanate
  • fubfenprox
  • pyrethrin
  • resmethrin
  • imidacloprid
  • acetamiprid
  • thiamethoxam
  • nitenpyram
  • thiacloprid
  • dinotefuran
  • clothianidin
  • imidaclothiz
  • chlorfluazuron
  • diflubenzuron
  • lufenuron
  • teflubenzuron
  • triflumuron
  • novaluron
  • flufenoxuron
  • hexaflumuron
  • bistrifluoron
  • noviflumuron
  • buprofezin
  • cyromazine
  • methoxyfenozide
  • tebufenozide
  • halofenozide
  • chromafenozide
  • endosulfan
  • fipronil
  • ethiprole
  • pyrafluprole
  • pyriprole
  • flubendiamide
  • chlorantraniliprole (Rynaxypyr)
  • cyazypyr
  • emamectin
  • emamectin benzoate
  • abamectin
  • ivermectin
  • milbemectin
  • lepimectin
  • tebufenpyrad
  • fenpyroximate
  • pyridaben
  • fenazaquin
  • pyrimidifen
  • tolfenpyrad
  • dicofol
  • cyenopyrafen
  • cyflumetofen
  • acequinocyl
  • fluacrypyrin
  • bifenazate
  • diafenthiuron
  • etoxazole
  • clofentezine
  • spinosad
  • triarathen
  • tetradifon
  • propargite
  • hexythiazox
  • bromopropylate
  • chinomethionat
  • amitraz
  • pyrifluquinazone
  • pymetrozine
  • flonicamid
  • pyriproxyfen
  • diofenolan
  • chlorfenapyr
  • metaflumizone
  • indoxacarb
  • chlorpyrifos
  • spirodiclofen
  • spiromesifen
  • spirotetramat
  • pyridalyl
  • spinetoram
  • acephate
  • triazophos
  • profenofos
  • fenamiphos
  • 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoro-ethyl)amino}furan-2(5H)-one
  • cadusaphos
  • carbaryl
  • carbofuran
  • ethoprophos
  • thiodicarb
  • aldicarb
  • metamidophos
  • methiocarb
  • sulfoxaflor


Additionally likewise preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient of group (II) selected from

  • Bacillus firmus I-1582
  • dichloropropene
  • dimethoate
  • metaldehyde
  • methomyl
  • cartap
  • oil (for example petroleum)
  • chloropicrin
  • carbosulfan
  • dichlorvos
  • metam-sodium
  • phoxim
  • monocrotophos
  • oxamyl
  • methidathion
  • fenitrothion
  • terbufos
  • fluensulfone
  • imicyafos
  • 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetra dec-11-en-10-one
  • 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine


Additionally more preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

  • acrinathrin
  • alpha-cypermethrin
  • betacyfluthrin
  • cyhalothrin
  • cypermethrin
  • deltamethrin
  • lambda-cyhalothrin
  • gamma-cyhalothrin
  • transfluthrin
  • cyfluthrin
  • bifenthrin
  • tefluthrin
  • imidacloprid
  • acetamiprid
  • thiamethoxam
  • thiacloprid
  • dinotefuran
  • clothianidin
  • lufenuron
  • triflumuron
  • novaluron
  • flufenoxuron
  • buprofezin
  • methoxyfenozide
  • tebufenozide
  • fipronil
  • ethiprole
  • flubendiamide
  • chlorantraniliprole (Rynaxypyr)
  • cyazypyr
  • emamectin
  • emamectin benzoate
  • abamectin
  • milbemectin
  • tebufenpyrad
  • fenpyroximate
  • diafenthiuron
  • spinosad
  • flonicamid
  • chlorfenapyr
  • metaflumizone
  • indoxacarb
  • chlorpyrifos
  • spirodiclofen
  • spiromesifen
  • spirotetramat
  • pyridalyl
  • spinetoram
  • acephate
  • triazophos
  • profenofos
  • fenamiphos
  • 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoro-ethyl)amino}furan-2(5H)-one
  • cadusaphos
  • carbaryl
  • carbofuran
  • ethoprophos
  • thiodicarb
  • aldicarb
  • metamidophos
  • methiocarb
  • sulfoxaflor


Additionally likewise more preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

  • Bacillus firmus I-1582
  • dichloropropene
  • dimethoate
  • methomyl
  • imicyafos
  • fluensulfone
  • 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one
  • 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine


Even more preferred active ingredient combinations comprise exactly one active ingredient of the formula (I-1-1) to (I-1-60) and one or more active ingredients from group (II).




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Additionally even more preferred active ingredient combinations comprise the mixtures of active ingredients of the formula (I-1-1) to (I-1-60) and one or more active ingredients from group (II) specified hereinafter.


These mixtures are present preferably in a mixing ratio of 80:20 to 99:1. Mention should be made by way of example of the mixture I-1-1/I-1-7, the compound of the formula I-1-1 being present relative to the compound of the formula I-1-7 in a mixing ratio of 80:20 to 99:1. Mention should likewise be made by way of example of the mixture I-1-2/I-1-8, the compound of the formula I-1-2 being present relative to the compound of the formula I-1-8 in a mixing ratio of 80:20 to 99:1.


I-1-1-/1-1-7,


1-1-2/1-1-8,


1-1-3/1-1-9,


I-1-4/1-1-10,


I-1-5/1-1-11,


I-1-6/1-1-12,


I-1-13/I-1-1-19,


1-1-14/1-1-20,


I-1-15/I-1-21,


I-1-16/I-1-22,


I-1-17/I-1-23,


I-1-18/I-1-24,


1-1-25/1-1-31,


1-1-26/1-1-32,


I-1-27/I-1-33,


1-1-28/1-1-34,


I-1-29/I-1-35,


I-1-30/I-1-36,


1-1-37/1-1-43,


1-1-38/1-1-44,


I-1-39/I-1-45,


I-1-40/I-1-46,


I-1-41/I-1-47,


I-1-42/I-1-48,


I-1-49/I-1-55,


I-1-50/I-1-56,


I-1-51/I-1-57,


I-1-52/I-1-58,


I-1-53/I-1-59,


I-1-54/I-1-60.


Especially preferred are combinations comprising the active ingredient (I-1-1) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-2) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-3) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-4) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-5) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-6) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-7) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-8) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (1-1-9) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-10) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-11) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-12) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-13) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-14) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-15) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-16) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-17) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-18) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-19) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-20) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-21) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-22) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-23) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-24) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-25) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-26) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-27) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-28) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-29) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-30) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-31) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-32) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-33) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-34) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-35) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-36) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-37) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-38) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-39) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-40) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-41) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-42) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-43) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-44) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-45) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-46) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-47) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-48) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-49) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-50) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-51) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-52) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-53) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-54) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-55) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-56) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-57) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-58) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-59) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


Especially preferred are combinations comprising the active ingredient (I-1-60) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.


The active ingredient combinations may additionally also comprise further fungicidally, acaricidally or insecticidally active mixture components.


When the active ingredients are present in particular weight ratios in the inventive active ingredient combinations, the improved effect is manifested. However, the weight ratios of the active ingredients in the active ingredient combinations can be varied within a relatively wide range. In general, the inventive combinations comprise active ingredients of the formula (I) to the mixing partner from group (II) in a ratio of 625:1 to 1:625; preferably in the preferred and more preferred mixing ratios specified in Table 1 below:

    • the mixing ratios are based on weight ratios. The ratio should be understood as the active ingredient of the formula (I):mixing partner to active ingredient of the formula (I):mixing partner.


















Preferred
More
Most




mixing
preferred
preferred



Mixing partner
ratio
mixing ratio
mixing ratio



















1.
acrinathrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


2.
alpha-cypermethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


3.
betacyfluthrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


4.
cyhalothrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


5.
cypermethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


6.
deltamethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


7.
esfenvalerate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


8.
etofenprox
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


9.
fenpropathrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


10.
fenvalerate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


11.
flucythrinate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


12.a
lambda-cyhalothrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


12.b
gamma-cyhalothrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


13.
permethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


14.
tau-fluvalinate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


15.
transfluthrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


16.
zeta-cypermethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


17.
cyfluthrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


18.
bifenthrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


19.
tefluthrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


20.
eflusilanate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


21.
fubfenprox
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


22.
pyrethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


23.
resmethrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


24.
imidacloprid
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


25.
acetamiprid
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


26.
thiamethoxam
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


27.
nitenpyram
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


28.
thiacloprid
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


29.
dinotefuran
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


30.
clothianidin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


31.
imidaclothiz
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


32.
chlorfluazuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


33.
diflubenzuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


34.
lufenuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


35.
teflubenzuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


36.
triflumuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


37.
novaluron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


38.
flufenoxuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


39.
hexaflumuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


40.
bistrifluoron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


41.
noviflumuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


42.
buprofezin
625:1 to 1:625
125:1 to 1:125
25:1 to 1:25


43.
cyromazine
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


44.
methoxyfenozide
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


45.
tebufenozide
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


46.
halofenozide
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


48.
chromafenozide
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


49.
endosulfan
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


50.
fipronil
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


51.
ethiprole
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


52.
pyrafluprole
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


53.
pyriprole
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


54.
flubendiamide
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


55.
chlorantraniliprole
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5



(Rynaxypyr)





56.
cyazypyr
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


57.
emamectin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


58.
emamectin benzoate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


59.
abamectin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


60.
ivermectin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


61.
milbemectin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


62.
lepimectin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


63.
tebufenpyrad
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


64.
fenpyroximate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


65.
pyridaben
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


66.
fenazaquin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


67.
pyrimidifen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


68.
tolfenpyrad
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


69.
dicofol
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


70.
cyenopyrafen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


71.
cyflumetofen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


72.
acequinocyl
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


73.
fluacrypyrin
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


74.
bifenazate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


75.
diafenthiuron
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


76.
etoxazole
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


77.
clofentezine
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


78.
spinosad
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


79.
triarathen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


80.
tetradifon
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


81.
propargite
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


82.
hexythiazox
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


83.
bromopropylate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


84.
chinomethionat
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


85.
amitraz
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


86.
pyrifluquinazone
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


87.
pymetrozine
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


88.
flonicamid
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


89.
pyriproxyfen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


90.
diofenolan
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


91.
chlorfenapyr
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


92.
metaflumizone
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


93.
indoxacarb
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


94.
chlorpyrifos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


95.
spirodiclofen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


96.
spiromesifen
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


97.
spirotetramat
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


98.
pyridalyl
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


99.
spinetoram
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


100.
acephate
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


101.
triazophos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


102.
profenofos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


103.
fenamiphos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


104.
4-{[(6-chloropyrid-
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5



3-yl)methyl](2,2-






difluoro-ethyl)






amino}-furan-






2(5H)-one





105.
cadusaphos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


106.
carbaryl
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


107.
carbofuran
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


108.
ethoprophos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


109.
thiodicarb
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


110.
aldicarb
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


111.
metamidophos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


112.
methiocarb
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


113.
sulfoxaflor
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


114.
imicyafos
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


115.
fluensulfone
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5


116.

Bacillus
firmus

500:1 to 1:500
125:1 to 1:125
25:1 to 1:25



1-1582





117.
11-(4-chloro-2,6-
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5



dimethylphenyl)-






12-hydroxy-1,4-






dioxa-9-azadispiro






[4.2.4.2]tetradec-






11-en-10-one





118.
2-{6-[2-(5-
125:1 to 1:125
25:1 to 1:25
5:1 to 1:5



fluoropyridin-3-






yl)-1,3-thiazol-5-






yl]pyridin-2-






yl}pyrimidine









The inventive active ingredient combinations, given good plant tolerance, favourable homeotherm toxicity and good environmental compatibility, are suitable for protecting plants and plant organs, for increasing harvest yields, for improving the quality of the harvested material and for controlling animal pests, especially insects, arachnids, helminths, nematodes and molluscs, which are encountered in agriculture, in horticulture, in animal husbandry, in forests, in gardens and leisure facilities, in the protection of stored products and of materials, and in the hygiene sector. They can preferably be used as crop protection compositions. They are active against normally sensitive and resistant species and against all or some stages of development. The abovementioned pests include:


From the order of the Anoplura (Phthiraptera), for example, Damalinia spp., Haematopinus spp., Linognathus spp., Pediculus spp., Trichodectes spp.


From the class of the Arachnida, for example, Acarus spp., Aceria sheldoni, Aculops spp., Aculus spp., Amblyomma spp., Amphitetranychus viennensis, Argas spp., Boophilus spp., Brevipalpus spp., Bryobia praetiosa, Chorioptes spp., Dermanyssus gallinae, Eotetranychus spp., Epitrimerus pyri, Eutetranychus spp., Eriophyes spp., Halotydeus destructor, Hemitarsonemus spp., Hyalomma spp., Ixodes spp., Latrodectus mactans, Metatetranychus spp., Nuphersa spp., Oligonychus spp., Ornithodoros spp., Panonychus spp., Phyllocoptruta oleivora, Polyphagotarsonemus latus, Psoroptes spp., Rhipicephalus spp., Rhizoglyphus spp., Sarcoptes spp., Scorpio maurus, Stenotarsonemus spp., Tarsonemus spp., Tetranychus spp., Vasates lycopersici.


From the class of the Bivalva, for example, Dreissena spp.


From the order of the Chilopoda, for example, Geophilus spp., Scutigera spp.


From the order of the Coleoptera, for example, Acalymma vittatum, Acanthoscelides obtectus, Adoretus spp., Agelastica alni, Agriotes spp., Amphimallon solstitialis, Anobium punctatum, Anoplophora spp., Anthonomus spp., Anthrenus spp., Apion spp., Apogonia spp., Atomaria spp., Attagenus spp., Bruchidius obtectus, Bruchus spp., Cassida spp., Cerotoma trifurcata, Ceutorrhynchus spp., Chaetocnema spp., Cleonus mendicus, Conoderus spp., Cosmopolites spp., Costelytra zealandica, Ctenicera spp., Curculio spp., Cryptorhynchus lapathi, Cylindrocopturus spp., Dermestes spp., Diabrotica spp., Dichocrocis spp., Diloboderus spp., Epilachna spp., Epitrix spp., Faustinus spp., Gibbium psylloides, Hellula undalis, Heteronychus arator, Heteronyx spp., Hylamorpha elegans, Hylotrupes bajulus, Hypera postica, Hypothenemus spp., Lachnosterna consanguinea, Lema spp., Leptinotarsa decemlineata, Leucoptera spp., Lissorhoptrus oryzophilus, Lixus spp., Luperodes spp., Lyctus spp., Megascelis spp., Melanotus spp., Meligethes aeneus, Melolontha spp., Migdolus spp., Monochamus spp., Naupactus xanthographus, Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorrhynchus spp., Oxycetonia jucunda, Phaedon cochleariae, Phyllophaga spp., Phyllotreta spp., Popillia japonica, Premnotrypes spp., Psylliodes spp., Ptinus spp., Rhizobius ventralis, Rhizopertha dominica, Sitophilus spp., Sphenophorus spp., Sternechus spp., Symphyletes spp., Tanymecus spp., Tenebrio molitor, Tribolium spp., Trogoderma spp., Tychius spp., Xylotrechus spp., Zabrus spp.


From the order of the Collembola, for example, Onychiurus armatus.


From the order of the Diplopoda, for example, Blaniulus guttulatus.


From the order of the Diptera, for example, Aedes spp., Agromyza spp., Anastrepha spp., Anopheles spp., Asphondylia spp., Bactrocera spp., Bibio hortulanus, Calliphora erythrocephala, Ceratitis capitata, Chironomus spp., Chrysomyia spp., Cochliomyia spp., Contarinia spp., Cordylobia anthropophaga, Culex spp., Cuterebra spp., Dacus oleae, Dasyneura spp., Delia spp., Dermatobia hominis, Drosophila spp., Echinocnemus spp., Fannia spp., Gastrophilus spp., Hydrellia spp., Hylemyia spp., Hyppobosca spp., Hypoderma spp., Liriomyza spp. Lucilia spp., Musca spp., Nezara spp., Oestrus spp., Oscinella frit, Pegomyia spp., Phorbia spp., Prodiplosis spp., Psila rosae, Rhagoletis spp., Stomoxys spp., Tabanus spp., Tannia spp., Tetanops spp., Tipula spp.


From the class of the Gastropoda, for example, Arion spp., Biomphalaria spp., Bulinus spp., Deroceras spp., Galba spp., Lymnaea spp., Oncomelania spp., Pomacea spp., Succinea spp.


From the class of the helminths, for example, Ancylostoma duodenale, Ancylostoma ceylanicum, Acylostoma braziliensis, Ancylostoma spp., Ascaris lumbricoides, Ascaris spp., Brugia malayi, Brugia timori, Bunostomum spp., Chabertia spp., Clonorchis spp., Cooperia spp., Dicrocoelium spp, Dictyocaulus filaria, Diphyllobothrium latum, Dracunculus medinensis, Echinococcus granulosus, Echinococcus multilocularis, Enterobius vermicularis, Faciola spp., Haemonchus spp., Heterakis spp., Hymenolepis nana, Hyostrongulus spp., Loa Loa, Nematodirus spp., Oesophagostomum spp., Opisthorchis spp., Onchocerca volvulus, Ostertagia spp., Paragonimus spp., Schistosomen spp., Strongyloides fuelleborni, Strongyloides stercoralis, Stronyloides spp., Taenia saginata, Taenia solium, Trichinella spiralis, Trichinella nativa, Trichinella britovi, Trichinella nelsoni, Trichinella pseudopsiralis, Trichostrongulus spp., Trichuris trichiura, Wuchereria bancrofti.


It is also possible to control protozoa, such as Eimeria.


From the order of the Heteroptera, for example, Anasa tristis, Antestiopsis spp., Blissus spp., Calocoris spp., Campylomma livida, Cavelerius spp., Cimex spp., Collaria spp., Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp., Euschistus spp., Eurygaster spp., Heliopeltis spp., Horcias nobilellus, Leptocorisa spp., Leptoglossus phyllopus, Lygus spp., Macropes excavatus, Miridae, Monalonion atratum, Nezara spp., Oebalus spp., Pentomidae, Piesma quadrata, Piezodorus spp., Psallus spp., Pseudacysta persea, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophora spp., Stephanitis nashi, Tibraca spp., Triatoma spp.


From the order of the Homoptera, for example, Acyrthosipon spp., Acrogonia spp., Aeneolamia spp., Agonoscena spp., Aleurodes spp., Aleurolobus barodensis, Aleurothrixus spp., Amrasca spp., Anuraphis cardui, Aonidiella spp., Aphanostigma piri, Aphis spp., Arboridia apicalis, Aspidiella spp., Aspidiotus spp., Atanus spp., Aulacorthum solani, Bemisia spp., Brachycaudus helichrysii, Brachycolus spp., Brevicoryne brassicae, Calligypona marginata, Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlorita onukii, Chromaphis juglandicola, Chrysomphalus ficus, Cicadulina mbila, Coccomytilus halli, Coccus spp., Cryptomyzus ribis, Dalbulus spp., Dialeurodes spp., Diaphorina spp., Diaspis spp., Drosicha spp., Dysaphis spp., Dysmicoccus spp., Empoasca spp., Eriosoma spp., Erythroneura spp., Euscelis bilobatus, Ferrisia spp., Geococcus coffeae, Hieroglyphus spp., Homalodisca coagulata, Hyalopterus arundinis, Icerya spp., Idiocerus spp., Idioscopus spp., Laodelphax striatellus, Lecanium spp., Lepidosaphes spp., Lipaphis erysimi, Macrosiphum spp., Mahanarva spp., Melanaphis sacchari, Metcalfiella spp., Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus spp., Nasonovia ribisnigri, Nephotettix spp., Nilaparvata lugens, Oncometopia spp., Orthezia praelonga, Parabemisia myricae, Paratrioza spp., Parlatoria spp., Pemphigus spp., Peregrinus maidis, Phenacoccus spp., Phloeomyzus passerinii, Phorodon humuli, Phylloxera spp., Pinnaspis aspidistrae, Planococcus spp., Protopulvinaria pyriformis, Pseudaulacaspis pentagona, Pseudococcus spp., Psylla spp., Pteromalus spp., Pyrilla spp., Quadraspidiotus spp., Quesada gigas, Rastrococcus spp., Rhopalosiphum spp., Saissetia spp., Scaphoides titanus, Schizaphis graminum, Selenaspidus articulatus, Sogata spp., Sogatella furcifera, Sogatodes spp., Stictocephala festina, Tenalaphara malayensis, Tinocallis caryaefoliae, Tomaspis spp., Toxoptera spp., Trialeurodes spp., Trioza spp., Typhlocyba spp., Unaspis spp., Viteus vitifolii, Zygina spp.


From the order of the Hymenoptera, for example, Athalia spp., Diprion spp., Hoplocampa spp., Lasius spp., Monomorium pharaonis, Vespa spp.


From the order of the Isopoda, for example, Armadillidium vulgare, Oniscus asellus and Porcellio scaber.


From the order of the Isoptera, for example, Acromyrmex spp., Atta spp., Cornitermes cumulans, Microtermes obesi, Odontotermes spp., Reticulitermes spp.


From the order of the Lepidoptera, for example, Acronicta major, Adoxophyes spp., Aedia leucomelas, Agrotis spp., Alabama spp., Amyelois transitella, Anarsia spp., Anticarsia spp., Argyroploce spp., Barathra brassicae, Borbo cinnara, Bucculatrix thurberiella, Bupalus piniarius, Busseola spp., Cacoecia spp., Caloptilia theivora, Capua reticulana, Carpocapsa pomonella, Carposina niponensis, Cheimatobia brumata, Chilo spp., Choristoneura spp., Clysia ambiguella, Cnaphalocerus spp., Cnephasia spp., Conopomorpha spp., Conotrachelus spp., Copitarsia spp., Cydia spp., Dalaca noctuides, Diaphania spp., Diatraea saccharalis, Earias spp., Ecdytolopha aurantium, Elasmopalpus lignosellus, Eldana saccharina, Ephestia kuehniella, Epinotia spp., Epiphyas postvittana, Etiella spp., Eulia spp., Eupoecilia ambiguella, Euproctis spp., Euxoa spp., Feltia spp., Galleria mellonella, Gracillaria spp., Grapholitha spp., Hedylepta spp., Helicoverpa spp., Heliothis spp., Hofmannophila pseudospretella, Homoeosoma spp., Homona spp., Hyponomeuta padella, Kakivoria flavofasciata, Laphygma spp., Laspeyresia molesta, Leucinodes orbonalis, Leucoptera spp., Lithocolletis spp., Lithophane antennata, Lobesia spp., Loxagrotis albicosta, Lymantria spp., Lyonetia spp., Malacosoma neustria, Maruca testulalis, Mamestra brassicae, Mocis spp., Mythimna separata, Nymphula spp., Oiketicus spp., Oria spp., Orthaga spp., Ostrinia spp., Oulema oryzae, Panolis flammea, Parnara spp., Pectinophora spp., Perileucoptera spp., Phthorimaea spp., Phyllocnistis citrella, Phyllonorycter spp., Pieris spp., Platynota stultana, Plusia spp., Plutella xylostella, Prays spp., Prodenia spp., Protoparce spp., Pseudaletia spp., Pseudoplusia includens, Pyrausta nubilalis, Rachiplusia nu, Schoenobius spp., Scirpophaga spp., Scotia segetum, Sesamia spp., Sparganothis spp., Spodoptera spp., Stathmopoda spp., Stomopteryx subsecivella, Synanthedon spp., Tecia solanivora, Thermesia gemmatalis, Tinea pellionella, Tineola bisselliella, Tortrix spp., Trichoplusia spp., Tuta absoluta, Virachola spp.


From the order of the Orthoptera, for example, Acheta domesticus, Blatta orientalis, Blattella germanica, Dichroplus spp., Gryllotalpa spp., Leucophaea maderae, Locusta spp., Melanoplus spp., Periplaneta americana, Schistocerca gregaria.


From the order of the Siphonaptera, for example, Ceratophyllus spp., Xenopsylla cheopis.


From the order of the Symphyla, for example, Scutigerella spp.


From the order of the Thysanoptera, for example, Anaphothrips obscurus, Baliothrips biformis, Drepanothris reuteri, Enneothrips flavens, Frankliniella spp., Heliothrips spp., Hercinothrips femoralis, Rhipiphorothrips cruentatus, Scirtothrips spp., Taeniothrips cardamoni, Thrips spp.


From the order of the Thysanura, for example, Lepisma saccharina.


The phytoparasitic nematodes include, for example, Aphelenchoides spp., Bursaphelenchus spp., Ditylenchus spp., Globodera spp., Heterodera spp., Longidorus spp., Meloidogyne spp., Pratylenchus spp., Radopholus similis, Trichodorus spp., Tylenchulus semipenetrans, Xiphinema spp.


The active ingredient combinations can be converted to the customary formulations, such as solutions, emulsions, wettable powders, suspensions, powders, dusts, pastes, soluble powders, granules, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, and also microencapsulations in polymeric substances.


These formulations are produced in a known manner, for example by mixing the active ingredients with extenders, i.e. liquid solvents, and/or solid carriers, optionally with the use of surfactants, i.e. emulsifiers and/or dispersants, and/or foam formers.


If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents essentially include: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics and chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulfoxide, and also water.


Useful solid carriers include:


for example ammonium salts and ground natural minerals, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals, such as finely divided silica, alumina and silicates; suitable solid carriers for granules are for example crushed and fractionated natural rocks, such as calcite, marble, pumice, sepiolite, dolomite and synthetic granules of inorganic and organic meals, and granules of organic material, such as sawdust, coconut shells, maize cobs and tobacco stalks; suitable emulsifiers and/or foam formers are for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates and protein hydrolysates; suitable dispersants are for example lignosulphite waste liquors and methylcellulose.


In the formulations it is possible to use tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids. Further additives may be mineral and vegetable oils.


It is possible to use dyes such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.


The formulations contain generally between 0.1 and 95% by weight of active ingredient, preferably between 0.5 and 90%.


The inventive active ingredient combinations may be present in commercially available formulations and in the use forms, prepared from these formulations, as a mixture with other active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators or herbicides. The insecticides include, for example, phosphoric esters, carbamates, carboxylic esters, chlorinated hydrocarbons, phenylureas, substances produced by microorganisms, etc.


A mixture with other known active ingredients, such as herbicides, or with fertilizers and growth regulators, is also possible.


When used as insecticides, the inventive active ingredient combinations may also be present in their commercially available formulations and in the use forms, prepared from these formulations, as a mixture with synergists. Synergists are compounds which enhance the action of the active ingredients, without any need for the synergist added to be active itself.


The active ingredient content of the use forms prepared from the commercially available formulations may vary within wide limits. The active ingredient concentration of the application forms may be from 0.0000001 to 95% by weight of active ingredient, preferably between 0.0001 and 1% by weight.


The compounds are applied in a customary manner appropriate for the use forms.


All plants and plant parts can be treated in accordance with the invention. Plants are understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant varieties which are protectable and non-protectable by plant breeders' rights. Plant parts are understood to mean all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples of which include leaves, needles, stalks, stems, flowers, fruit bodies, fruits, seeds, roots, tubers and rhizomes. The plant parts also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds.


The inventive treatment of the plants and plant parts with the active ingredient combinations is effected directly or by allowing them to act on the surroundings, habitat or storage space thereof by the customary treatment methods, for example by dipping, spraying, vaporizing, pouring on, nebulizing, scattering, painting on, and, in the case of propagation material, especially in the case of seeds, also by applying one or more coats.


As already mentioned above, it is possible to treat all plants and their parts in accordance with the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetical engineering, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above.


More preferably, plants of the plant cultivars which are each commercially available or in use are treated in accordance with the invention.


Depending on the plant species or plant cultivars, and the location and growth conditions (soils, climate, vegetation period, diet) thereof, the inventive treatment may also result in superadditive (“synergistic”) effects. For example, possibilities include reduced application rates and/or broadening of the activity spectrum and/or an increase in the activity of the compounds and compositions usable in accordance with the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or higher nutritional value of the harvested products, increased storage life and/or processibility of the harvested products, which exceed the effects normally to be expected.


The transgenic plants or plant cultivars (those obtained by genetic engineering) which are to be treated with preference in accordance with the invention include all plants which, through the genetic modification, received genetic material which imparts particular advantageous useful properties (“traits”) to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or a higher nutritional value of the harvested products, better storage life and/or processibility of the harvested products. Further and particularly emphasized examples of such properties are an improved defence of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active ingredients. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), maize, soya beans, potatoes, cotton, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to maize, soya beans, potatoes, cotton and oilseed rape. Traits that are emphasized are in particular increased defense of the plants against insects by toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as “Bt plants”). Traits that are additionally particularly emphasized are the increased tolerance of the plants to certain active herbicidal ingredients, for example imidazolinones, sulphonylureas, glyphosate or phosphinothricin (for example the “PAT” gene). The genes which impart the desired traits in question may also be present in combinations with one another in the transgenic plants. Examples of “Bt plants” include maize varieties, cotton varieties, soya varieties and potato varieties which are sold under the trade names YIELD GARD® (for example maize, cotton, soya), KnockOut® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucotn® (cotton) and NewLeaf® (potato). Examples of herbicide-tolerant plants include maize varieties, cotton varieties and soya varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example maize, cotton, soya), Liberty Link® (tolerance to phosphinothricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) also include the varieties sold under the Clearfield® name (for example maize). Of course, these statements also apply to plant cultivars which have these genetic traits or genetic traits which are still to be developed and will be developed and/or marketed in the future.


The plants listed can be treated according to the invention in a particularly advantageous manner with the active compound mixture according to the invention. The preferred ranges stated above for the mixtures also apply to the treatment of these plants. Particular emphasis is given to the treatment of plants with the mixtures specifically mentioned in the present text.


The good insecticidal and acaricidal action of the inventive active ingredient combinations is evident from the examples which follow. While the individual active ingredients have weaknesses in their action, the combinations exhibit an action which exceeds a simple sum of actions.


A synergistic effect in insecticides and acaricides is present whenever the action of the active ingredient combinations is greater than the sum of the actions of the active ingredients applied individually.


USE EXAMPLES

The expected action for a given combination of two active ingredients can be calculated according to S. R. Colby, Weeds 15 (1967), 20-22 as follows:


If




  • X is the kill rate, expressed in % of the untreated control, in the case of use of active ingredient A in an application rate of m g/ha or in a concentration of m ppm,

  • Y is the kill rate, expressed in % of the untreated control, in the case of use of active ingredient B in an application rate of n g/ha or in a concentration of n ppm, and

  • E is the kill rate, expressed in % of the untreated control, in the case of use of active ingredients A and B in application rates of m and n g/ha or in a concentration of m and n ppm,


    then







E
=

X
+
Y
-



X
·
Y

100

.






If the actual kill rate is greater than that calculated, the kill rate of the combination is superadditive, which means that a synergistic effect is present. In this case, the kill rate actually observed must be greater than the value calculated from the above formula for the expected kill rate (E).


Example A

Myzus persicae Test

Solvent:






    • 78 parts by weight of acetone

    • 1.5 parts by weight of dimethylformamide


      Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether





To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.


Cabbage leaves (Brassica oleracea) severely infested by the green peach aphid (Myzus persicae) are treated by spraying with the active ingredient formulation in the desired concentration.


After the desired time, the kill in % is determined. 100% means that all aphids have been killed; 0% means that no aphids have been killed. The kill rates determined are entered into Colby's formula.


In this test, the following active ingredient combinations according to the present invention, for example, exhibited a synergistic enhancement in activity compared to the active ingredients applied individually:









TABLE A-1








Myzus
persicae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 1 d












compound (I-1-2)/compound (I-1-8)***
4
0



0.8
0



0.16
0



0.032
0


compound (I-1-1)/compound (I-1-7)***
4
80



0.8
0



0.16
0



0.032
0


abamectin
0.16
0










compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 0.16
found*
calc.**


abamectin (5:1)

70
0


inventive












acephate
100
0










compound (I-1-2)/compound (I-1-8)*** +
 4 + 100
found*
calc.**


acephate (1:25)

80
0


inventive












acrinathrin
0.8
0










compound (I-1-2)/compound (I-1-8)*** +
0.032 + 0.8 
found*
calc.**


acrinathrin (1:25)

90
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.032 + 0.8 
found*
calc.**


acrinathrin (1:25)

80
0


inventive












alpha-cypermethrin
0.16
70










compound (I-1-2)/compound (I-1-8)*** +
0.16 + 0.16
found*
calc.**


alpha-cypermethrin (1:1)

90
70 


inventive













Bacillus
firmus strain I-1582
250
0










compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 250 
found*
calc.**



Bacillus
firmus I-1582 (1:312.5)

100 
80 


inventive












bifenthrin
0.8
80










compound (I-1-1)/compound (I-1-7)*** +
0.8 + 0.8
found*
calc.**


bifenthrin (1:1)

100 
80 


inventive












β-cyfluthrin
0.16
70



0.032
0










compound (I-1-2)/compound (I-1-8)*** +
 0.16 + 0.032
found*
calc.**


β-cyfluthrin (5:1)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 0.16
found*
calc.**


β-cyfluthrin (5:1)

90
70 


inventive












buprofezin
500
0













compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 500 
found*
calc.**


buprofezin (1:625)

70
0


inventive












cadusaphos
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


cadusaphos (1:25)

90
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


cadusaphos (1:25)

90
0


inventive












carbaryl
500
0










compound (I-1-2)/compound (I-1-8)*** +
 4 + 500
found*
calc.**


carbaryl (1:125)

90
0


inventive












carbofuran
20
70










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


carbofuran (1:25)

90
70 


inventive












chlorpyrifos
4
80










compound (I-1-2)/compound (I-1-8)*** +
0.16 + 4  
found*
calc.**


chlorpyrifos (1:25)

100 
80 


inventive












clothianidin
20
70










compound (I-1-2)/compound (I-1-8)*** +
 4 + 20
found*
calc.**


clothianidin (1:5)

90
70 


inventive












cypermethrin
4
80










compound (I-1-1)/compound (I-1-7)*** +
0.8 + 4  
found*
calc.**


cypermethrin (1:5)

100 
80 


inventive












deltamethrin
0.8
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 0.8
found*
calc.**


deltamethrin (1:1)

100 
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 0.8
found*
calc.**


deltamethrin (1:1)

80
0


inventive












diafenthiuron
100
0










compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 100 
found*
calc.**


diafenthiuron (1:125)

70
0


inventive












emamectin benzoate
0.8
0



0.16
0










compound (I-1-2)/compound (I-1-8)*** +
  4 + 0.8
found*
calc.**


emamectin benzoate (5:1)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 0.16
found*
calc.**


emamectin benzoate (5:1)

70
0


inventive












ethiprole
4
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 4  
found*
calc.**


ethiprole (1:5)

80
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 4  
found*
calc.**


ethiprole (1:5)

70
0


inventive












flonicamid
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


flonicamid (1:25)

80
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


flonicamid (1:25)

70
0


inventive












gamma-cyhalothrin
0.032
0










compound (I-1-1)/compound (I-1-7)*** +
 0.16 + 0.032
found*
calc.**


gamma-cyhalothrin (5:1)

70
0


inventive












imidacloprid
0.8
0










compound (I-1-2)/compound (I-1-8)*** +
0.032 + 0.8 
found*
calc.**


imidacloprid (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.032 + 0.8 
found*
calc.**


imidacloprid (1:25)

70
0


inventive












indoxacarb
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


indoxacarb (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


indoxacarb (1:25)

80
0


inventive












L-cyhalothrin
0.16
0










compound (I-1-2)/compound (I-1-8)*** +
0.16 + 0.16
found*
calc.**


L-cyhalothrin (1:1)

80
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.16 + 0.16
found*
calc.**


L-cyhalothrin (1:1)

90
0


inventive












metaflumizone
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20
found*
calc.**


metaflumizone (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


metaflumizone(1:25)

70
0


inventive












methamidophos
100
80



20
0










compound (I-1-2)/compound (I-1-8)*** +
 4 + 100
found*
calc.**


methamidophos (1:25)

100 
80 


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


methamidophos (1:25)

90
0


inventive












methiocarb
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


methiocarb (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


methiocarb (1:25)

70
0


inventive












milbemectin
0.8
0










compound (I-1-1)/compound (I-1-7)*** +
0.8 + 0.8
found*
calc.**


milbemectin (1:1)

70
0


inventive












pyridalyl
4
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 4  
found*
calc.**


pyridalyl (1:5)

70
0


inventive












spinetoram
4
0










compound (I-1-2)/compound (I-1-8)*** +
4 + 4
found*
calc.**


spinetoram (1:1)

70
0


inventive












spirodiclofen
100
0



20
0










compound (I-1-2)/compound (I-1-8)*** +
 4 + 100
found*
calc.**


spirodiclofen (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


spirodiclofen (1:25)

70
0


inventive












spiromesifen
4
0










compound (I-1-1)/compound (I-1-7)*** +
0.8 + 4  
found*
calc.**


spiromesifen (1:5)

70
0


inventive












sulfoxaflor
0.16
0










compound (I-1-1)/compound (I-1-7)*** +
0.16 + 0.16
found*
calc.**


sulfoxaflor (1:1)

70
0


inventive












tebufenpyrad
0.8
0










compound (I-1-1)/compound (I-1-7)*** +
0.8 + 0.8
found*
calc.**


tebufenpyrad (1:1)

70
0


inventive












thiacloprid
20
80










compound (I-1-2)/compound (I-1-8)*** +
 4 + 20
found*
calc.**


thiacloprid (1:5)

100 
80 


inventive












thiamethoxam
20
70










compound (I-1-2)/compound (I-1-8)*** +
 4 + 20
found*
calc.**


thiamethoxam (1:5)

100 
70 


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 4  
found*
calc.**


thiamethoxam (1:5)

90
70 


inventive












thiodicarb
20
0










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


thiodicarb (1:25)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
0.8 + 20 
found*
calc.**


thiodicarb (1:25)

70
0


inventive












transfluthrin
20
70










compound (I-1-2)/compound (I-1-8)*** +
0.8 + 20 
found*
calc.**


transfluthrin (1:25)

90
70 


inventive












triazophos
100
0










compound (I-1-2)/compound (I-1-8)*** +
 0.8 + 100
found*
calc.**


triazophos (1:125)

70
0


inventive





compound (I-1-1)/compound (I-1-7)*** +
 0.8 + 100
found*
calc.**


triazophos (1:125)

70
0


inventive












4-{[(6-CHLOROPYRID-3-
20
0










YL)METHYL](2,2-





DIFLUOROETHYL)AMINO}FURAN-





2(5H)-ONE





compound (I-1-1)/compound (I-1-7)*** +
  20 + 0.16
found*
calc.**


4-{[(6-CHLOROPYRID-3-

70
0


YL)METHYL](2,2-





DIFLUOROETHYL)AMINOIFURAN-





2(5H)-ONE (125:1)





inventive












pymetrozine
100
0










compound (I-1-1)/compound (I-1-7)*** +
 4 + 100
found*
calc.**


pymetrozine (1:25)

100 
0


inventive












cyromazine
100
0










compound (I-1-1)/compound (I-1-7)*** +
 4 + 100
found*
calc.**


cyromazine (1:25)

70
0


inventive
















TABLE A-2








Myzus
persicae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 6d













compound (I-1-2)/compound
0.16
 0



(I-1-8)***
0.032
 0



compound (I-1-1)/compound
0.16
 70



(I-1-7)***
0.032
 0



acetamiprid
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + acetamiprid (1: 5)

 70
 0


inventive





aldicarb
0.8
 0



compound (I-1-2)/compound
0.16 + 0.8 
found*
calc.**


(I-1-8)*** + aldicarb (1: 5)

 80
 0


inventive





chlorfenapyr
0.8
 0




0.16
 0



compound (I-1-2)/compound
0.16 + 0.8 
found*
calc.**


(I-1-8)*** + chlorfenapyr (1: 5)

 80
 0


inventive





compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + chlorfenapyr (1: 5)

 70
 0


inventive





clothianidin
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + clothianidin (1: 5)

 70
 0


inventive





cyantraniliprole
0.16
 0



compound (I-1-2)/compound
0.032 + 0.16 
found*
calc.**


(I-1-8)*** + cyantraniliprole

 80
 0


(1: 5) inventive





compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + cyantraniliprole

 70
 0


(1: 5) inventive





diafenthiuron
20
 70



compound (I-1-2)/compound
0.16 + 20  
found*
calc.**


(I-1-8)*** + diafenthiuron

100
70


(1: 125) inventive





ethoprophos
4
 0



compound (I-1-2)/compound

found*
calc.**


(I-1-8)*** + ethoprophos (1: 25)
0.16 + 4  
 80
 0


inventive





fenamiphos
0.8
 0



compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + fenamiphos (1: 25)

 70
 0


inventive





11-(4-CHLORO-2,6-
0.8
 0



DIMETHYLPHENYL)-12-





HYDROXY-1,4-DIOXA-9-





AZADISPIRO[4.2.4.2]





TETRADEC-11-EN-10-ONE





compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + 11-(4-CHLORO-

 70
 0


2,6-DIMETHYLPHENYL)-12-





HYDROXY-1,4-DIOXA-9-





AZADISPIRO[4.2.4.2]





TETRADEC-11-EN-10-ONE





(1: 25) inventive





fipronil
0.16
 0



compound (I-1-2)/compound
0.16 + 0.16
found*
calc.**


(I-1-8)*** + fipronil (1: 1)

 80
 0


inventive





flufenoxuron
0.8
 0



compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + flufenoxuron (1: 25)

 70
 0


inventive





methoxyfenozide
4
 0



compound (I-1-2)/compound
0.16 + 4  
found*
calc.**


(I-1-8)*** + methoxyfenozide

100
 0


(1: 25) inventive





milbemectin
0.032
 0



compound (I-1-1)/compound
0.032 + 0.032
found*
calc.**


(I-1-7)*** + milbemectin (1: 1)

 70
 0


inventive





tebufenozide
4
 0



compound (I-1-2)/compound
0.16 + 4  
found*
calc.**


(I-1-8)*** + tebufenozide (1: 25)

100
 0


inventive





tebufenpyrad
0.16
 0



compound (I-1-2)/compound
0.16 + 0.16
found*
calc.**


(I-1-8)*** + tebufenpyrad (1: 1)

 80
 0


inventive





triflumuron
20
 0




4
 0



compound (I-1-2)/compound
0.16 + 20  
found*
calc.**


(I-1-8)*** + triflumuron (1: 125)

 90
 0


inventive





compound (I-1-1)/compound
0.032 + 4   
found*
calc.**


(I-1-7)*** + triflumuron (1: 125)

 70
 0


inventive





spinetoram
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8 
found*
calc.**


(I-1-7)*** + spinetoram (1: 5)

 90
70


inventive





thiacloprid
0.8
 80



compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + thiacloprid (1: 25)

100
80


inventive





2-{6-[2-(5-FLUOROPYRIDIN-
0.8
 70



3-YL)-1,3-THIAZOL-5-





YL]PYRIDIN-2-YL}





PYRIMIDINE





compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + 2-{6-[2-(5-

100
70


FLUOROPYRIDIN-3-YL)-1,3-





THIAZOL-5-YL]PYRIDIN-2-





YL}PYRIMIDINE (1: 25)





inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.






Example B

Phaedon cochleariae Larvae Test

Solvent:






    • 78 parts by weight of acetone

    • 1.5 parts by weight of dimethylformamide


      Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether





To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.


Cabbage leaves (Brassica oleracea) are treated by spraying with the active ingredient formulation of the desired concentration and populated with larvae of the mustard beetle (Phaedon cochleariae) while the leaves are still moist.


After the desired period of time, the kill rate in % is determined. 100% means that all beetle larvae have been killed; 0% means that none of the beetle larvae have been killed. The kill rates determined are entered into Colby's formula.


In this test, the following active ingredient combinations according to the present application exhibit a synergistic enhancement in activity compared to the active ingredients applied individually:









TABLE B-1








Phaedon
cochleariae larvae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 2d













compound (I-1-2)/compound
0.16
 50



(I-1-8)***
0.032
 0



compound (I-1-1)/compound
0.16
 67



(I-1-7)***





aldicarb
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8 
found*
calc.**


(I-1-7)*** + aldicarb (1: 5)

100
67


inventive





β-cyfluthrin
0.032
 0



compound (I-1-2)/compound
 0.16 + 0.032
found*
calc.**


(I-1-8)*** + β-cyfluthrin (5: 1)

 67
50


inventive





cyantraniliprole
0.16
 0



compound (I-1-2)/compound
0.032 + 0.16 
found*
calc.**


(I-1-8)*** + cyantraniliprole

 33
 0


(1: 5) inventive





dinotefuran
20
 0



compound (I-1-2)/compound
0.16 + 20  
found*
calc.**


(I-1-8)*** + dinotefuran

 83
50


(1: 125) inventive





compound (I-1-1)/compound
0.16 + 20  
found*
calc.**


(I-1-7)*** + dinotefuran (1: 125)

100
67


inventive





fipronil
0.16
 67



compound (I-1-2)/compound
0.16 + 0.16
found*
calc.**


(I-1-8)*** + fipronil (1: 1)

100
83.5


inventive





compound (I-1-1)/compound
0.16 + 0.16
found*
calc.**


(I-1-7)*** + fipronil (1: 1)

100
83.5


inventive





profenophos
4
 0



compound (I-1-2)/compound
0.16 + 4  
found*
calc.**


(I-1-8)*** + profenophos (1: 25)

 83
50


inventive





tebufenozide
4
 0



compound (I-1-2)/compound
0.16 + 4  
found*
calc.**


(I-1-8)*** + tebufenozide (1: 1)

 83
50


inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.













TABLE B-2








Phaedon
cochleariae larvae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 6d













compound (I-1-2)/compound
0.032
 0



(I-1-8)***





compound (I-1-1)/compound
0.16
 83



(I-1- 7)***
0.032
 0



abamectin
0.032
 0



compound (I-1-1)/compound
 0.16 + 0.032
found*
calc.**


(I-1-7)*** + abamectin (5: 1)

100
83


inventive





acephate
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + acephate (1: 25)

100
83


inventive





cyantraniliprole
0.16
 0



compound (I-1-2)/compound
0.032 + 0.16 
found*
calc.**


(I-1-8)*** + cyantraniliprole (1: 5)

 50
 0


inventive





compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + cyantraniliprole (1: 5)

100
 0


inventive





cypermethrin
0.16
 0



compound (I-1-2)/compound
0.032 + 0.16 
found*
calc.**


(I-1-8)*** + cypermethrin (1: 5)

 33
 0


inventive





emamectin benzoate
0.032
 0



compound (I-1-1)/compound
 0.16 + 0.032
found*
calc.**


(I-1-7)*** + emamectin benzoate

100
83


(5: 1) inventive





ethoprophos
0.8
 0



compound (I-1-2)/compound
0.032 + 0.8 
found*
calc.**


(I-1-8)*** + ethoprophos (1: 25)

 33
 0


inventive





flubendiamide
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8 
found*
calc.**


(I-1-7)*** + flubendiamide (1: 5)

100
83


inventive





novaluron
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8 
found*
calc.**


(I-1-7)*** + novaluron (1: 5)

100
83


inventive





profenophos
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + profenophos (1: 25)

100
83


inventive





spirodiclofen
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + spirodiclofen (1: 25)

100
83


inventive





tebufenpyrad
0.16
 0



compound (I-1-1)/compound
0.16 + 0.16
found*
calc.**


(I-1-7)*** + tebufenpyrad (1: 1)

100
83


inventive





triflumuron
4
 0



compound (I-1-2)/compound
0.032 + 4   
found*
calc.**


(I-1-8)*** + triflumuron (1: 125)

 50
 0


inventive





spinetoram
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + spinetoram (1: 5)

 33
 0


inventive





pyridalyl
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + pyridalyl (1: 25)

100
83


inventive





methoxyfenozide
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8 
found*
calc.**


(I-1-7)*** + methoxyfenozide

100
83


(1: 5) inventive





2-{6-[2-(5-FLUOROPYRIDIN-3-
0.16
 0



YL)-1,3-THIAZOL-5-





YL]PYRIDIN-2-





YL}PYRIMIDINE





compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + 2-{6-[2-(5-

100
83


FLUOROPYRIDIN-3-YL)-1,3-





THIAZOL-5-YL]PYRIDIN-2-





YL}PYRIMIDINE (1: 25)





inventive





cyromazine
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + cyromazine (1: 25)

100
83


inventive





cyflumetofen
4
 0



compound (I-1-1)/compound
0.16 + 4  
found*
calc.**


(I-1-7)*** + Cyflumetofen (1: 25)

100
83


inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.






Example C

Spodoptera frugiperda Larvae Test

Solvent:






    • 78 parts by weight of acetone

    • 1.5 parts by weight of dimethylformamide


      Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether





To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.


Cabbage leaves (Brassica oleracea) are treated by spraying with the active ingredient formulation of the desired concentration and populated with larvae of the army worm (Spodopter frugiperda) while the leaves are still moist.


After the desired time, the kill in % is determined. 100% means that all caterpillars have been killed; 0% means that none of the caterpillars have been killed. The kill rates determined are entered into Colby's formula.


In this test, the following active ingredient combinations according to the present application exhibit a synergistic enhancement in activity compared to the active ingredients applied individually:









TABLE C-1








Spodoptera
frugiperda larvae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 2d













compound (I-1-2)/compound
0.16
33



(I-1-8)***
0.032
17



fenpyroximate
0.8
 0



compound (I-1-2)/compound
0.16 + 0.8 
found*
calc.**


(I-1-8)*** + fenpyroximate

83
33


(1: 5) inventive





gamma-cyhalothrin
0.032
17



compound (I-1-2)/compound
 0.16 + 0.032
found*
calc.**


(I-1-8)*** + fenpyroximate

83
44.39


(5: 1) inventive





indoxacarb
0.8
50



compound (I-1-2)/compound
0.032 + 0.8 
found*
calc.**


(I-1-8)*** + indoxacarb (1: 25)

83
58.5


inventive





triazophos
4
 0



compound (I-1-2)/compound
0.032 + 4   
found*
calc.**


(I-1-8)*** + triazophos (1: 125)

67
17


inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.















TABLE C-2






Concentration
Kill rate


Active ingredient
in g/ha
in % after 6d


















compound (I-1-1)/compound
0.16
 33



(I-1-7)***
0.032
 0



carbaryl
4
 0



compound (I-1-1)/compound
0.032 + 4
found*
calc.**


(I-1-7)*** + carbaryl (1: 125)

 50
 0


inventive





fluensulfone
2000
 0



compound (I-1-1)/compound
0.16 + 2000
found*
calc.**


(I-1-7)*** + fluensulfone

 67
33


(1: 12500) inventive





flufenoxuron
0.8
 0



compound (I-1-1)/compound
0.032 + 0.8
found*
calc.**


(I-1-7)*** + flufenoxuron

100
 0


(1: 25) inventive





imicyafos
45
 0



compound (I-1-1)/compound
0.16 + 45
found*
calc.**


(I-1-7)*** + imicyafos

 83
33


(1: 281.25) inventive





L-cyhalothrin
0.032
 0



compound (I-1-1)/compound
0.032 + 0.032
found*
calc.**


(I-1-7)*** + L-cyhalothrin (1: 1)

 83
 0


inventive





lufenuron
0.8
 17



compound (I-1-1)/compound
0.032 + 0.8
found*
calc.**


(I-1-7)*** + lufenuron (1: 25)

 67
17


inventive





novaluron
0.8
 67



compound (I-1-1)/compound
0.032 + 0.8
found*
calc.**


(I-1-7)*** + novaluron (1: 25)

 83
67


inventive





profenophos
4
 17



compound (I-1-1)/compound
0.032 + 4
found*
calc.**


(I-1-7)*** + profenophos

 67
17


(1: 125) inventive





chloranthraniliprole
0.032
 50



compound (I-1-1)/compound
0.032 + 0.032
found*
calc.**


(I-1-7)*** + chloranthraniliprole

100
50


(1: 1) inventive





spinosad
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16
found*
calc.**


(I-1-7)*** + spinosad (1: 5)

 33
 0


inventive





tebufenozide
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16
found*
calc.**


(I-1-7)*** + tebufenozide (1: 5)

 33
 0


inventive





pyridalyl
4
 0



compound (I-1-1)/compound
0.16 + 4
found*
calc.**


(I-1-7)*** + pyridalyl (1: 25)

 50
33


inventive





methoxyfenozide
0.8
 0



compound (I-1-1)/compound
0.16 + 0.8
found*
calc.**


(I-1-7)*** + methoxyfenozide

 67
33


(1: 5) inventive





cyromazine
4
 0



compound (I-1-1)/compound
0.16 + 4
found*
calc.**


(I-1-7)*** + cyromazine (1: 25)

 50
33


inventive





cyflumetofen
4
 17



compound (I-1-1)/compound
0.16 + 4
found*
calc.**


(I-1-7)*** + cyflumetofen

 50
33


(1: 25) inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.






Example D

Tetranychus Test (OP-Resistant/Spray Treatment)

Solvent:






    • 78 parts by weight of acetone

    • 1.5 parts by weight of dimethylformamide


      Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether





To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.


Discs of bean leaves (Phaseolus vulgaris) infested by all stages of the two-spotted spider mite (Tetranychus urticae) are sprayed with an active ingredient formulation of the desired concentration.


After the desired period of time, the effect in % is determined. 100% means that all of the spider mites have been killed; 0% means that none of the spider mites have been killed.


In this test, the following active ingredient combination according to the present application exhibited a synergistic enhancement in activity compared to the active ingredients applied individually:









TABLE D-1








Tetranychus
urticae test










Concentration
Kill rate


Active ingredient
in g/ha
in % after 2d













compound (I-1-2)/compound
4
 0



(I-1-8)***
0.8
 0




0.16
 0




0.032
 0



compound (I-1-1)/compound
4
 0



(I-1-7)***
0.8
 0




0.16
 0




0.032
 0



acrinathrin
4
20




0.8
 0



compound (I-1-2)/compound
0.16 + 4  
found*
calc.**


(I-1-8)*** + acrinathrin (1: 25)

70
20


inventive





alpha-cypermethrin
4
 0



compound (I-1-2)/compound
4 + 4
found*
calc.**


(I-1-8)*** + alpha-cypermethrin

80
 0


(1: 1) inventive





compound (I-1-1)/compound
4 + 4
found*
calc.**


(I-1-7)*** + alpha-cypermethrin

70
 0


(1: 1) inventive





bifenthrin
0.16
 0



compound (I-1-2)/compound
0.16 + 0.16
found*
calc.**


(I-1-8)*** + bifenthrin (1: 1)

70
 0


inventive





compound (I-1-1)/compound
0.16 + 0.16
found*
calc.**


(I-1-7)*** + bifenthrin (1: 1)

40
 0


inventive





carbaryl
500
10



compound (I-1-2)/compound
 4 + 500
found*
calc.**


(I-1-8)*** + carbaryl (1: 125)

50
10


inventive





chlorfenapyr
4
10



compound (I-1-2)/compound
0.8 + 4  
found*
calc.**


(I-1-8)*** + chlorfenapyr (1: 5)

70
10


inventive





compound (I-1-1)/compound
0.8 + 4  
found*
calc.**


(I-1-7)*** + chlorfenapyr (1: 5)

80
10


inventive





diafenthiuron
100
 0



compound (I-1-2)/compound
  0.8 + 100
found*
calc.**


(I-1-8)*** + diafenthiuron (1: 125)

70
 0


inventive





emamectin benzoate
0.032
 0



compound (I-1-2)/compound
 0.16 + 0.032
found*
calc.**


(I-1-8)*** + emamectin benzoate

30
 0


(5: 1) inventive





fenamiphos
20
 0



compound (I-1-2)/compound
0.8 + 20 
found*
calc.**


(I-1-8)*** + fenamiphos (1: 25)

20
 0


inventive





fenpyroximate
0.8
 0



compound (I-1-2)/compound
0.032 + 0.8 
found*
calc.**


(I-1-8)*** + fenpyroximate (1: 25)

50
 0


inventive





compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + fenpyroximate (1: 25)

80
 0


inventive





flubendiamide
20
 0



compound (I-1-1)/compound
 4 + 20
found*
calc.**


(I-1-7)*** + flubendiamide (1: 5)

30
 0


inventive





fluensulfone
2000
 0



compound (I-1-1)/compound
  4 + 2000
found*
calc.**


(I-1-7)*** + fluensulfone (1: 500)

30
 0


inventive





gamma-cyhalothrin
0.8
 0



compound (I-1-1)/compound
0.8 + 0.8
found*
calc.**


(I-1-7)*** + gamma-cyhalothrin

30
 0


(1: 1) inventive





lufenuron
100
 0



compound (I-1-1)/compound
 4 + 100
found*
calc.**


(I-1-7)*** + lufenuron (1: 25)

20
 0


inventive





milbemectin
0.032
50



compound (I-1-1)/compound
0.032 + 0.032
found*
calc.**


(I-1-7)*** + milbemectin (1: 1)

80
 0


inventive





spinosad
20
20



compound (I-1-2)/compound
 4 + 20
found*
calc.**


(I-1-8)*** + spinosad (1: 5)

60
20


inventive





spirodiclofen
100
 0



compound (I-1-2)/compound
 4 + 100
found*
calc.**


(I-1-8)*** + spirodiclofen (1: 25)

70
 0


inventive





compound (I-1-1)/compound
 4 + 100
found*
calc.**


(I-1-7)*** + spirodiclofen (1: 25)

80
 0


inventive





spirotetramat
4
 0



compound (I-1-2)/compound
0.8 + 4  
found*
calc.**


(I-1-8)*** + spirotetramat (1: 5)

20
 0


inventive





tebufenpyrad
0.16
 0



compound (I-1-1)/compound
0.032 + 0.16 
found*
calc.**


(I-1-7)*** + tebufenpyrad (1: 5)

40
 0


inventive





thiodicarb
100
 0



compound (I-1-2)/compound
 4 + 100
found*
calc.**


(I-1-8)*** + thiodicarb (1: 25)

50
 0


inventive





compound (I-1-1)/compound
 4 + 100
found*
calc.**


(I-1-7)*** + thiodicarb (1: 25)

70
 0


inventive





4-{[(6-CHLOROPYRID-3-YL)
20
 0



METHYL](2,2-DIFLUOROETHYL)





AMINO}FURAN-2(5H)-ONE





compound (I-1-1)/compound
 4 + 20
found*
calc.**


(I-1-7)*** + 4-{[(6-CHLOROPYRID-

20
 0


3-YL)METHYL](2,2-





DIFLUOROETHYL)AMINO}





FURAN-2(5H)-ONE (1: 5)





inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.















TABLE D-2






Concentration
Kill rate


Active ingredient
in g/ha
in % after 6d


















compound (I-1-2)/compound
4
 0



(I-1-8)***
0.8
 0




0.16
 0




0.032
 0



compound (I-1-1)/compound
4
 10



(I-1-7)***
0.8
 10




0.16
 0




0.032
 0



acrinathrin
0.8
 40



compound (I-1-2)/compound
0.032 + 0.8 
found*
calc.**


(I-1-8)*** + acrinathrin (1: 25)

 70
40


inventive





compound (I-1-1)/compound
0.032 + 0.8 
found*
calc.**


(I-1-7)*** + acrinathrin (1: 25)

 80
40


inventive





abamectin
0.032
 80




0.0064
 0



compound (I-1-2)/compound
 0.16 + 0.032
found*
calc.**


(I-1-8)*** + abamectin (5: 1)

100
80


inventive





compound (I-1-1)/compound
 0.032 + 0.0064
found*
calc.**


(I-1-7)*** + abamectin (5: 1)

 70
 0


inventive





cadusaphos
20
 0



compound (I-1-2)/compound
0.8 + 20 
found*
calc.**


(I-1-8)*** + cadusaphos (1: 25)

 40
 0


inventive





carbaryl
500
 20



compound (I-1-2)/compound
 4 + 500
found*
calc.**


(I-1-8)*** + carbaryl (1: 125)

 70
20


inventive





chlorpyrifos
100
 0



compound (I-1-2)/compound
 4 + 100
found*
calc.**


(I-1-8)*** + chlorpyrifos (1: 25)

 30
 0


inventive





compound (I-1-1)/compound
 4 + 100
found*
calc.**


(I-1-7)*** + chlorpyrifos (1: 25)

 70
10


inventive





diafenthiuron
20
 10



compound (I-1-2)/compound
0.16 + 20  
found*
calc.**


(I-1-8)*** + diafenthiuron

 30
10


(1: 125) inventive





L-cyhalothrin
4
 20



compound (I-1-1)/compound
4 + 4
found*
calc.**


(I-1-7)*** + L-cyhalothrin (1: 1)

 70
28


inventive





spinetoram
4
 20



compound (I-1-2)/compound
4 + 4
found*
calc.**


(I-1-8)*** + spinetoram (1: 1)

 80
20


inventive





spiromesifen
20
 80




4
 70



compound (I-1-2)/compound
 4 + 20
found*
calc.**


(I-1-8)*** + spiromesifen (1: 5)

100
80


inventive





compound (I-1-1)/compound
0.8 + 4  
found*
calc.**


(I-1-7)*** + spiromesifen(1: 5)

 90
73


inventive





tebufenpyrad
4
 40



compound (I-1-2)/compound
4 + 4
found*
calc.**


(I-1-8)*** + tebufenpyrad (1: 1)

 90
40


inventive





compound (I-1-1)/compound
4 + 4
found*
calc.**


(I-1-7)*** + tebufenpyrad (1: 1)

 80
46


inventive





tefluthrin
20
 0



compound (I-1-2)/compound
 4 + 20
found*
calc.**


(I-1-8)*** + tefluthrin (1: 5)

 40
 0


inventive





*found = effect found


**calc. = effect calculated by Colby's formula


***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.





Claims
  • 1. An active ingredient combination comprising a synergistically active combination of at least one compound of formula (I-1) selected from the group consisting of
  • 2. An agrochemical composition comprising the active ingredient combination of claim 1, and at least one extender and/or surfactant.
  • 3. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 1 to act on animal pests and/or their habitat.
  • 4. A process for producing agrochemical compositions, comprising mixing the active ingredient combination of claim 1 with at least one extender and/or surfactant.
  • 5. The active ingredient combination of claim 1, wherein the ratio of a compound or compounds of formula (1-1) to a compound or compounds of group (II) is 1:1 to 1:25.
  • 6. The active ingredient combination of claim 1, wherein the ratio of a compound or compounds of formula (1-1) to a compound or compounds of group (II) is 5:1 to 1:5.
  • 7. The active ingredient combination of claim 1, wherein the compound of the formula (1-1-1) and the compound of the formula (1-1-7) is used.
  • 8. The active ingredient combination of claim 1, wherein the compound of the formula (1-1-2) and the compound of the formula (1-1-8) is used.
  • 9. The active ingredient combination of claim 1, wherein the insecticide and/or acaricide of the group (II) is cyflumetofen.
  • 10. The active ingredient combination of claim 1, wherein the insecticide and/or acaricide of the group (II) is cyromazine.
  • 11. The active ingredient combination of claim 1, wherein the insecticide and/or acaricide of the group (II) is pymetrozine.
  • 12. The active ingredient combination of claim 1, wherein the insecticide and/or acaricide of the group (II) is azadirachtin.
  • 13. The active ingredient combination of claim 1, wherein the insecticide and/or acaricide of the group (II) is cyclaniliprole.
  • 14. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 9 to act on animal pests and/or their habitat.
  • 15. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 10 to act on animal pests and/or their habitat.
  • 16. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 11 to act on animal pests and/or their habitat.
  • 17. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 12 to act on animal pests and/or their habitat.
  • 18. A method for controlling animal pests, comprising allowing the active ingredient combination of claim 13 to act on animal pests and/or their habitat.
Priority Claims (1)
Number Date Country Kind
10166439 Jun 2010 EP regional
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 13/161,960, filed Jun. 16, 2011, which claims priority to EP 10166439.9 filed Jun. 18, 2010 and U.S. 61/356,224 filed Jun. 18, 2010, the contents all of which are incorporated herein by reference in their entireties.

US Referenced Citations (18)
Number Name Date Kind
20040116744 Furuya et al. Jun 2004 A1
20070066617 Mita et al. Mar 2007 A1
20070129407 Koyanagi et al. Jun 2007 A1
20070142327 Funke et al. Jun 2007 A1
20080070863 Funke et al. Mar 2008 A1
20080305955 Bretschneider et al. Dec 2008 A1
20090076282 Toriyabe et al. Mar 2009 A1
20090111847 Li et al. Apr 2009 A1
20090247551 Jeschke et al. Oct 2009 A1
20090253749 Jeschke et al. Oct 2009 A1
20090259046 Hamamoto et al. Oct 2009 A1
20100029478 Alig et al. Feb 2010 A1
20100240705 Jeschke et al. Sep 2010 A1
20100292226 Funke et al. Nov 2010 A1
20110195998 Goto et al. Aug 2011 A1
20110212949 Bretschneider et al. Sep 2011 A1
20110257191 Fischer et al. Oct 2011 A1
20110306499 Bretschneider et al. Dec 2011 A1
Foreign Referenced Citations (37)
Number Date Country
0 539 588 May 1993 EP
2008-110953 May 2008 JP
2010-018586 Jan 2010 JP
02096882 Dec 2002 WO
03106457 Dec 2003 WO
2004046129 Jun 2004 WO
2005035486 Apr 2005 WO
2005048713 Jun 2005 WO
2005053393 Jun 2005 WO
2005053406 Jun 2005 WO
2005063094 Jul 2005 WO
2005077934 Aug 2005 WO
2005085216 Sep 2005 WO
2006043635 Apr 2006 WO
2006056433 Jun 2006 WO
2006089633 Aug 2006 WO
2006100288 Sep 2006 WO
2007017433 Feb 2007 WO
2007040280 Apr 2007 WO
2007057407 May 2007 WO
2007075459 Jul 2007 WO
2007101369 Sep 2007 WO
2007115643 Oct 2007 WO
2007115644 Oct 2007 WO
2007115646 Oct 2007 WO
2007144100 Dec 2007 WO
2007149134 Dec 2007 WO
2008066153 Jun 2008 WO
2008067911 Jun 2008 WO
2008072783 Jun 2008 WO
2008104503 Sep 2008 WO
2009049851 Apr 2009 WO
2010005692 Jan 2010 WO
2010006713 Jan 2010 WO
2010074747 Jul 2010 WO
2010074751 Jul 2010 WO
2011098408 Aug 2011 WO
Non-Patent Literature Citations (2)
Entry
International Search Report Based on Application No. PCT/EP2011/059988 dated Nov. 30, 2011.
Colby; “Calculating Synergistic and Antagonistic Responses of Herbicide Combinations”; Weeds; 1967; vol. 15; pp. 20-22.
Related Publications (1)
Number Date Country
20160037775 A1 Feb 2016 US
Provisional Applications (1)
Number Date Country
61356224 Jun 2010 US
Continuations (1)
Number Date Country
Parent 13161960 Jun 2011 US
Child 14887638 US